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Summary    
 Summary  
 
TAR-DNA binding protein (TDP-43) is a multifunctional ribonucleoprotein, which is 
involved in transcription, splicing and mRNA stablilisation. TDP-43 is predominantly 
localised in the nucleus but shuttles between nucleus and the cytoplasm. In a 
pathological situation it is depleted from the nucleus and found mislocalised in the 
cytoplasm where it is abnormally cleaved, phosphorylated, ubiquitinated and aggregated. 
TDP-43 has been implicated in wide range of neurodegenerative diseases including 
amyotrophic lateral sclerosis (ALS) and frontotemporal lobar degeneration-U (FTLD-U). 
The relative impact of the endogenous protein function, alteration and mutations on 
disease progression or pathology remains unclear.  
In this study I addressed many questions pertaining to TDP-43 biology with both random 
and strict comparable expression levels. This study focused on developing and 
characterising Drosophila models of TDP-43 proteinopathy. In addition, this study 
investigated the role of ALS/FTLD linked mutations and alterations on neural integrity 
utilising Drosophila as model system. A direct role of TDP-43 in neurodegeneration is 
highlighted by the fact that neuronal expression of human TDP-43 in Drosophila causes 
age- and dose-dependent locomotion deficits and early lethality. Further, targeted 
expression of TDP-43 to the developing fly eye results in a rough eye phenotype (REP).  
In this study TDP-43 RNA-binding was found to be absolutely required for toxicity. 
ALS/FTLD linked mutations and other reported pathological events like mislocalisation or 
truncation were relatively less toxic when compared to TDP-43 wild-type. Further I 
performed a large-scale toxicity modifier screen for TDP-43 induced toxicity using REP as 
readout. I identified novel modifiers of TDP-43-induced toxicity in this genetic screen. The 
most prominent candidates were RNA/DNA related genes, ubiquitin proteasome pathway 
related genes and neuron related genes. In addition, I found a novel protein interactor 
DBNDD2/CK1BP of TDP-43 in a yeast-2- hybrid screen. 
 In the end, I present a very potent model of TDP-43 proteinopathy, which recapitulates a 
wide range of neuropathological, biochemical and functional features of human TDP-43 
proteinopathy. Further working with this model I could uncover many endogenous 
functions and toxicity modifiers of TDP-43 induced toxicity. This study enhances our 
knowledge on TDP-43 biology and potentially widens future research strategies.
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1 Introduction 
 Neurodegenerative disorders are diseases in which the nervous system (NS) 
progressively and irreversibly deteriorates. Problems with movements and/or cognitive 
functioning (dementia) characterise these sporadic and congenital conditions. 
Neurodegenerative disorders are an increasing social and economic burden for the 
nations of the world, thus understanding the biology of these diseases is an absolute 
requirement for better health care and cure. Accumulation of intracellular or 
extracellular protein aggregates pathologically characterises a majority of 
neurodegenerative diseases, e.g. Alzheimer’s Disease (AD) is defined by senile 
plaques and neurofibrillary tangles composed of β-amyloid and microtubule-associated 
protein Tau, respectively [1]. In Parkinson’s Disease (PD) intracellular Lewy bodies 
composed of aggregated α-Synuclein are a characteristic hallmark [2].  
 The discovery of Tar DNA-binding protein (TDP-43) as the principal component 
of ubiquitinated inclusions in amytrophic lateral sclerosis (ALS) and frontotemporal 
lobar dementia with ubiquitin-positive inclusions (FTLD-U) added a new member to the 
long list of aggregate forming proteins in various neurodegenerative disorders. 
1.1 TDP-43 proteinopathies 
  The major TDP-43-associated diseases are ALS and FTLD-U. Both diseases 
are characterised by ubiquitin-positive, Tau- and α-Synuclein-negative inclusions. The 
nature of these inclusions was unknown until the landmark discovery by Neumann et 
al. in 2006 identifying TDP-43 as major component of ubiquitin positive aggregates in 
both diseases [3]. TDP-43 was identified as pathological protein in many other 
neurodegenerative diseases later, thus placing all of these diseases under the 
summarising term TDP-43 proteinopathies [4] (Table 1). 
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Table 1: TDP-43-associated diseases (adapted from [5]) 
 
Major TDP-43 diseases 
 Amyotrophic lateral sclerosis with/without dementia  
 Frontotemporal degeneration with motor neuron disease 
 Frontotemporal degeneration with ubiquitin-positive, Tau and  
α-Synuclein-negative inclusions 
 Frontotemporal dementia with inclusion body myopathy and Paget’s disease 
of bone 
 Perry syndrome 
 
Disease with secondary TDP-43 pathology 
 Parkinsonism-dementia complex/Amyotrophic lateral sclerosis on geographic 
isolates 
 Alzheimer’s disease 
 Pick’s disease 
 Corticobasal degeneration 
 Argyrophilic grain disease 
 Parkinson’s disease, dementia with Lewy bodies  
 Huntington’s disease 
 Myopathies (inclusion body myositis, oculopharyngeal muscular dystrophy, 
distal myopathies with rimmed vacuoles, polymyositis with mitochondrial 
pathology, polymyositis) 
 
 
 ALS and FTLD-U overlap clinically. Both diseases share similar pathological 
feature and genetics, which suggests that they might represent different phenotypes of 
the same neurodegenerative disorder [6, 7]. Further, TDP-43 aggregates were 
detected in the hypoglossal nucleus in all cases of ALS, all cases of FTLD with motor 
neuron disease (FTLD-MND) and in some of the cases of primary lateral sclerosis 
(PLS) [8]. Thus, substantiating the suggestion that TDP-43 is the common pathologic 
substrate linking FTLD and ALS [4]. 
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Figure 1: Molecular classification of FTLD-U and ALS. 
(A) Ubiquitinated inclusions are present in ALS and FTLD-U. The majority of disease cases 
contains TDP-43 inclusions, so can be classified as FTLD-TDP and ALS-TDP. A small subset 
of cases has pathological FUS, hence classified as FTLD-FUS and ALS-FUS. Misfolded SOD1 
is present in ubiquitinated inclusions only in cases with SOD1 mutations, ALS-SOD. In some 
cases of FTLD-U, the identity of ubiquitinated protein is unknown. FTLD-UPS, indicating that 
markers of ubiquitin-proteasome system label inclusions in this case (adapted from [9]).(B) 
Presence of TDP-43 in FTLD and ALS. Approximately 50% of cases of clinical FTLD show 
TDP-43 pathology, with the remainder characterised by either Tau pathology or other forms of 
neuropathology, notably FUS inclusions. TDP-43 pathology is observed in the vast majority of 
ALS cases. Additionaly, overlap syndromes between FTLD and ALS most frequently show 
TDP-43 pathology. A subset of individuals with FTLD-Tau have mutations in MAPT, while 
some FTLD-TDP cases are associated with mutations in GRN. Mutations in TDP-43 can be 
found in FTLD-TDP, FTLD-MND and ALS cases and the vast majority of these mutations 
manifest clinically as ALS.  
(MAPT- microtubule- associated protein Tau, SOD- Superoxide dismutase 1, soluble, FUS- 
fused in sarcoma), GRN –Progranulin (adapted from [10]) 
 
1.2 Amyotrophic lateral sclerosis (ALS) 
 ALS (also known as Lou Gehrig’s Disease or creeping paralysis [11]) is the 
most common form of motor neuron disease (MND), firstly described in 1865 by the 
french neurologist Jean-Martin Charcot [12]. As the name suggests, amyotrophy refers 
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to muscle wasting and lateral sclerosis refers to degeneration of cortical primary motor 
neurons (upper motor neurons) and their descending axons in the lateral columns of 
the spinal cord that innervate the lower motor neurons (Figure 2). This leads to 
weakness, spasticity, and paralysis followed by death. ALS also involves several non-
motor system and subcortical structures; cognitive deficits in ALS patients are also 
reported [13]. 
 
Figure 2: Schematic view of upper and lower motor neurons. 
Cell bodies of upper motor neuron (shown in red) reside within the motor cortex and innervate 
the lower motor neurons in the brain stem or the spinal cord. The lower motor neurons (shown 
in green) directly innervate muscles (adapted from [14]). 
 
 Approximately 90% of ALS cases are sporadic (sALS), the remaning 10% are 
inherited in a dominant manner i.e. familial ALS (fALS). ALS is affecting 1.5 - 3 per 
100,000 people with a typical age of onset between 40 to 70 years [15, 16]. It 
progresses rapidly with average survival of only 3 years after diagnosis [17]. fALS is 
associated with numerous genetic loci including mutations in six genes: Cu/Zn 
superoxide dismutase (SOD1), Alsin, Senataxin, Vesicle-associated/synaptobrevin-
associated membrane protein B (VAMP), Dynactin and C9orf72. Mutations in the 
C9orf72 are the most common cause of ALS and FTLD-U [18, 19]. SOD1-linked ALS 
does not share the same pathology. All ubiquitinated inclusions (UBIs) in ALS are 
positive for TDP-43 except UBIs in fALS caused by SOD1 mutations [20]. Thus SOD1- 
linked ALS seems to represent an atypical variant of the disease. 
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 Almost 95% of ALS cases have intracytoplasmic deposits of ubiquitinated, 
hyperphosphorylated TDP-43 in motor neurons appearing as round or skein-like 
inclusions. Gross pathological changes observed in ALS are atrophy of the precentral 
gyrus in brain, shrinkage, sclerosis and pallor of the corticospinal tracts, thinning of the 
spinal ventral roots and hypoglossal nerves followed by atrophy of the somatic and 
bulbar muscles [21]. Death is primarily caused by hypercarbic respiratory failure upon 
progressive weakness of respiratory musculature [15]. There is no cure yet available, 
only palliative support is provided to address physical, emotional and psychosocial 
needs of patients. Riluzole (a glutamate antagonist) is the only approved drug 
providing modest life prolonging effect [22]. 
1.3 Frontotemporal lobar dementia (FTLD) 
 FTLD is a clinical syndrome, which refers to a clinically, genetically, and 
pathologically heterogenous group of neurodegenerative disorders. FTLD accounts for 
5 - 15% of all dementia cases [23]. It is the second most prevalent form of dementia in 
those under 65 years of age, after AD [24]. FTLD prevalence estimates are ranging 
between 3.3 and 25.4 per 100,000 [25]. In FTLD, frontal and temporal lobes of the 
brain are progressively degenerated resulting in changes of personality, common 
behaviour and/or language, with relative preservation of perception and memory [26, 
27]. Up to 40% of FTLD show a familial pattern of inheritance with three different 
genetic abnormalities associated with FTLD-U pathology including mutations in 
Progranulin, Valosin-containing protein and C9orf 72 [28].  
 Based on neuropathology, FTLD brains can be separated in two major 
subtypes: brains with Tau-positive inclusions (also called taupathies) and brains with 
ubiqutinated inclusions or UBIs (negative for Tau, α-Synuclein, β-Amyloid), hence 
called FTLD-U. TDP-43 was found to be the main component of these UBIs henceforth 
also referred as FTLD-TDP [10]. TDP-43 associated FTLD (FTLD-TDP) has four 
subtypes based on appearance and localisation of inclusions. Subtype1 is 
characterised by long and tortuous Dystrophic neuritis (DNs) with relatively few 
neuronal cytoplasmic inclusions (NCIs) and no intranuclear inclusions (NII). Subtype 2 
has numerous NCIs, few DNs and no NIIs. Subtype 3 has numerous NCIs and DNs 
and occasional NIIs.  Subtype 4 pathology is characteristic for FTD with mutations in 
Valosin containing protein (VCP) and numerous NIIs and DNs, but only few NCIs.  
FTLD is accompanied by MND in approximately 10% cases [29]. Neuropathological 
findings of Ubiquitin-positive neuronal cytoplasmic inclusions (NCI) in lower motor 
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neurons, hippocampus and neocortex in both FTLD-U and MND [29] makes 
clinicopathological overlap between FTLD and MND well evident.  
1.4 TAR-DNA binding protein 43 (TDP-43) 
 As mentioned above TDP-43 is the major component of aggregates found in 
ALS and FTLD-U. Several mutations resulting in amino acid changes in the encoded 
protein have been linked to it (Figure 3). 
 The nuclear protein TDP-43 is expressed ubiquitously and encoded by the 
TARDBP gene located on chromosome 1p36.22. It is a highly conserved protein and 
found in all higher eukaryotic organisms including distant species like Drosophila 
melanogaster and Caenorhabditis elegans [30]. TDP-43 is a 414 amino acids long 
ribonucleoprotein with DNA/RNA binding properties. TDP-43 contains a nuclear 
localisation signal (NLS), a nuclear export signal (NES) enabling it to perform 
nucleocytoplasmic shuttling. In addition the protein harbours two RNA recognition 
motifs (RRM) and a C-terminal glycine-rich domain (CTD), known to promote protein-
protein interaction. In pathological condition, TDP-43 is mislocalised from nucleus to 
the cytoplasm in affected neurons. In the cytoplasm, TDP-43 is sequestered into 
inclusions, where it is found to be hyperphosphorylated, ubiquitinated, and C-terminally 
truncated. The high prevalence of missense mutations in TDP-43 found in familial and 
sporadic ALS suggests a putative role of mutant TDP-43 in disease.  
 
Figure 3: Protein domain structure of TDP-43. 
 The N-terminal domain TDP-43 contains a nuclear localisation signal sequence (NLS). Next to 
it, two RNA recognition motifs (RRM) and a nuclear export signal sequence (NES) are located. 
In the C-terminal domain (CTD) the majority of mutations are clustered. Mutations associated 
with disease (ALS and FTLD-U) are marked in red. Mutations where a clear disease 
association is yet to be reported are depicted in black. 
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  Extensive mutational analysis of the TARDBP gene discoverd missense 
mutations in patients with fALS as well as sALS [31-34]. The majority of mutations 
were found in exon six which codes for the end of the second RNA recognition motif 
(RRM) (up to amino acid 262) and the entire glycine-rich domain of TDP-43 protein 
[35], except one mutation D169G [33] which is localised in RRM1 and also found 
frameshift mutation Y374X [34] that creates a premature stop codon.  
 The CTD of TDP-43 shows a high level of conservation among mammals. 
Mutations in CTD were expected to influence protein-protein interactions and exon 
skipping as well as splicing regulatory activity. The CTD is involved in regulating 
alternative splicing as demonstrated with cystic fibrosis transmembrane conductance 
regulator (CTFR) and apolipoprotein A-11 (APOA2) [36]. The CTD has also been 
shown to bind several hnRNAP proteins involved in mRNA synthesis and has also 
been implicated as a transcriptional repressor [36]. Thus, in the CTD was thought to 
have deleterious effects on the function of the protein [35]. However, mutations have 
been identified in a relatively small proportion of ALS patients (4% of fALS and <1% of 
sALS [37]) and the role of mutations in disease mechanism is discussed. 
 Functional studies on TDP-43 mutations by various research groups resulted in 
conflicting reports on the toxicity induced by the mutations. Even the fundamental 
question whether the mutations represent a gain-of-function (GOF) or loss-of-function 
(LOF) is still debated. Several experimental investigations suggested that TDP-43 
mutations enhanced toxicity; for example TDP-43 mutations were reported to cause 
developmental defects in chick embryos [38].  Accordingly different mechanisms of 
toxicity have been suggested. In several studies, mutant TDP-43 was shown to have   
increased aggregation and toxicity [39, 40]. Some mutations result in substitution to 
threonine or serine residues and may increase TDP-43 phosphorylation, which may 
adversely affect various TDP-43 functions and the oligomerisation potential of TDP-43. 
Mutations may cause a toxic GOF through novel protein interaction or intracellular 
accumulation of TDP-43 fragments leading to apoptosis [40]. In contrast some groups 
found over-expression of TDP-43WT more toxic than overexpression of TDP-43 
mutations [41-43]. These studies imply that the mutations represent partial LOF. 
1.4.1 Physiological functions of TDP-43  
 TDP-43 derived its name from its discovery in 1995, when it was found to be 
interacting with HIV-1 TAR DNA sequence motif resulting in inhibition of transcription 
through an unknown mechanisms [44]. TDP-43 has been shown to be involved in 
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functions pertaining to transcriptional and translational regulation [45]. Its RRM1 
domain is crucial for binding to single strand RNA [46, 47]. Two recent studies 
identified RNAs that physically interact with TDP-43. Detailed analysis showed that 
TDP-43 preferentially, but not exclusively binds UG repeat sequences. TDP-43 binds 
to large proportions of the transcriptome (>6,000 RNA species) and mainly binds to the 
intronic sequences of unprocessed RNA. The RNA targets found were predominantly 
coding for proteins involved in synaptic activity or neuronal development [48, 49]. TDP-
43 controls its own expression through a negative feedback loop. RNA binding 
properties of the TDP-43 are essential for the autoregulatory activity through binding to 
3’UTR sequences in its own mRNA leading to the degradation of the transcript [50].  
 Another important role of TDP-43 is regulation of splicing [51]. The glycine-rich 
CTD of TDP-43 is capable of binding directly to several proteins of the heterogeneous 
nuclear ribonucleoprotein (hnRNP) family with well-known splicing regulatory activity 
[47]. TDP-43 regulates splicing of many transcripts for example human CFTR, 
apolipoprotein A2 (APOA2) and serine/arginine-rich splicing factor 2 (SC35). TDP-43 
expression effects mRNA turnover of cyclin-dependent kinase 6, histone deacetylase 6 
(HDAC6), futch, and low molecular weight neurofilaments. TDP-43 also plays an 
important role in stress granule formation. It localises to the perichromatin fibers in 
which miRNA biogenesis is thought to occur and binds to the primary miRNA 
processing Drosha complex. Another reported function of TDP-43 is to regulate 
retinoblastoma protein phosphorylation through the repression of CDK6 expression 
[52]. 
 TDP-43 is a neuronal activity-responsive factor functioning in the regulation of 
neuronal plasticity [53]. LOF studies in Drosophila substantiated the role of TDP-43 in 
neuronal integrity. Loss of TBPH (Drosophila homologue of TDP-43) induced 
neurodegenerative phenotypes for example deficient locomotive behaviour, reduced 
life span, anatomical defects in NMJs [54, 55] or decreased dendritic branching were 
observed suggesting an impaired neuronal connectivity [56, 57]. Interestingly, these 
phenotypes were rescued by expressing hTDP-43 [54, 56] or TBPH [57]. 
1.4.2 Pathological characteristics of TDP-43 
 In disease condition TDP-43 is mislocalised to the cytoplasm and N-terminally 
cleaved to generate C-terminal truncated fragments, CTFs (20-25 kDa). CTFs are 
hyperphosphorylated, ubiquitinated and found in inclusions. As mentioned before CTF 
inclusions are the neuropathological hallmarks in ALS and FTLD-U [3]. Because 
CHAPTER 1 – INTRODUCTION    9 
aberrant proteolytic cleavage/truncation during shuttling between nucleus and 
cytoplasm gives rise to CTF, it cannot regain access to the nucleus and accumulates 
in the cytoplasm. It is speculated that cytoplasmic accumulation leads to cell death by 
sequestering mRNA transcripts or components of the cellular transport machinery [58]. 
CTFs may also serve as seed for the aggregation into inclusions. The link between 
TDP-43 inclusions and neuronal death is unknown. TDP-43 aggregation correlates 
with the presence pathogenic events in disease. However, whether the aggregates are 
the cause or the result of pathological conditions is not clear. In some diseases, protein 
aggregates have been suggested to be protective [59]. However, TDP-43 inclusions do 
not seem to protect motor neurons from disease. Neuronophagia was observed in 
motoneurons containing TDP-43 inclusions, further suggesting inclusions to be a 
marker for motor neurons that are destined to die [60]. 
 In addition, over-expression of CTF (including pathologically associated CTF 
cleavage site Arg 208) and other synthetic CTFs recapitulated disease associated key 
features like phosphorylated and ubiqutinated cytoplasmic aggregates and splicing 
abnormalities in various cell culture based studies [61]. Considerable variablity in the 
type of CTF bands from clinical case to case is reported [36]. Thus, the possibility of 
distinct pathological processing in different subtypes cannot be ruled out [3]. 
 
 
Figure 4: Properties of physiological and pathological TDP-43 
(A) Under physiological conditions, TDP-43 is mainly located in nucleus. However, the protein 
is known to shuttle between the nucleus and the cytoplasm. TDP-43 is involved in regulating 
gene expression at the transcriptional level, by regulating RNA splicing and stability of mRNA. 
(B) Under pathophysiological conditions, TDP-43 is mislocalised from the nuclear 
compartment and aggregates in the cytoplasm. Pathological TDP-43 has been reported to be 
hyperphosphorylated and/ or ubiquitinated. Furthermore, CTF can be found in the disease 
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state. CTF has decreased solubility as compared to TDP-43 under physiological conditions, 
possibly making it more prone to aggregation. Such conditions might results in various LOF or 
toxic GOF mechanisms of disease pathogenesis. (Diagram adapted from [10]) 
 
 
 The two-hit hypothesis was suggested which presumes de novo generated CTF 
aggregated only in the presence of second hit such as the introduction of natively 
misfolded CTFs [62]. Some studies have found that CTFs are not always present and 
may not be absolutely necessary for TDP-43-induced neurodgeneration [63, 64]. In a 
non-human primate model overexpressing TDP-43, truncation was not a prerequisite 
for toxicity [65], whereas some investigations state that CTFs imparts neurotoxicity by 
a dominant-negative mechanism [66]. CTFs impair neurite growth during differentiation 
of cultured rodents neurons, TDP-43WT expression rescues this phenotype and 
knockdown of endogenous TDP-43 reproduces this phenotype [66].  
 Pathological significance of abnormal phosphorylation is also under 
investigation. Dephosphorylation treatment of the sarkosyl-insoluble fractions has 
shown abnormal phosphorylation at serine (S) S379, S403, S404, S409 and S410 in 
accumulated TDP-43 [67, 68]. Antibodies against S409/410 show robust staining of 
neuropathologic inclusions in most of TDP-43-based cases and ectopically CTF 
expressing cells [61, 69]. In vitro phosphorylation studies of recombinant human TDP-
43 shows that phosphorylation is the critical step in pathogenesis [68]. Phosphorylation 
might enhance TDP-43 oligomerisation but it is not a prerequisite for aggregation. 
Phosphorylation at S409/410 occurs late during the conversion of soluble to insoluble 
TDP-43 [69, 70]. Casein kinase1 (CK1) was identified to mediate phosphorylation of 
recombinant TDP-43 at 29 different sites in vitro [71]. Moreover, double-fluorescence 
experiments have shown that an anti-phospho antibody stains more neuronal 
cytoplasmic inclusions than an antibody against Ubiquitin. This suggests that 
ubiquitination of pathological TDP-43 is not vital and could be a later event in 
pathogenesis. Another study indicates that phosphorylation regulates proteasome 
mediated degradation and solubility of CTF [72]. 
 TDP-43 is intrinsically aggregation prone [73]. TDP-43 inclusions are not 
amyloid deposits [74]. The C-terminus has properties of a Q/N-rich prion domain, 
which is structurally close to yeast prions [75, 76]. Notably yeast prions contain a Q/N-
rich domain, which can adopt an alternative conformation that recruits the native form 
of the protein into inactive aggregates [76]. These inclusions are also present in the 
majority of ALS patients who do not have mutations in the TDP-43 gene suggesting 
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that mutations may not play a major role with regard to aggregation [36]. Studies have 
uncovered TDP-43 interacting with many proteins involved in autophagy and/or 
Ubiqutin proteasomal pathway (UPS) including ESCRTs, UBQLN, sequestosome1, 
and STAM-binding proteins. These studies project a role of UPS and autophagosome 
systems in TDP-43 turnover. But whether defect in clearance mechanism of TDP-43 
responsible for disease progression is still under investigation [65]. 
1.5 Modelling general neurodegeneration in flies 
 Drosophila is a proven model for neuroscience for more than 100 years as 
reviewed in [77]. 75% of human genes known to be associated with diseases have a 
Drosophila orthologue [78]. Using the Drosophila model system allows excellent 
genetic manipulation and in vivo readouts of pathology. Despite the enormous wealth 
of tools and methods exhibited by the fly, it would be unfair to expect fly models to 
completely recapitulate human diseases. Nevertheless, Drosophila models provide 
insightful entry point towards understanding the complexity of human 
neurodegenerative diseases. 
 Drosophila as a model has many advantages, for example simple handling 
techniques; it is easy and cheap to rear in lab and has a short and fast reproduction life 
cycle. It produces many progeny and has a short life span. The outside appearance 
provides numerous features for example compound eyes, wings, veins etc. which can 
be affected by mutations and resulting mutant phenotypes which can be easily scored. 
Some of the classical techniques used to study neurodegeneration in fly are histology, 
electron microscopy, electrophysiology, behaviour (climbing, aggression), and 
longevity analyses. The organisation of the Drosophila nervous system allows many 
opportunities to monitor selective neurodegeneration by using tools that allow one to 
mark and follow selected subsets of neurons as they are born, develop and 
degenerate.  
1.5.1 The UAS/Gal4 expression system 
The bipartite UAS/Gal4 ectopic expression system is commonly used in Drosophila to 
selectively over-express any transgene in a specific cell, tissue or developmental 
stages of interest. It is based on the yeast transcriptional activator Gal4 and its binding 
sites, the upstream activation sequences (UAS).  Enhancer trap constructs facilitating 
Gal4 expression were randomly inserted into the fly genome. If the insertion took place 
in the vicinity of an endogenous gene, Gal4 expression would mimic the expression 
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pattern of this particular gene.  There are now plenty of Gal4 driver lines expressing 
Gal4 in many different spatiotemporal manners [46, 79, 80].  The gene of interest is 
introduced into a different fly line and put under control of the upstream activation 
sequences (UAS). When these two fly lines are crossbred, both components of the 
system are joined togather. Gal4 is produced binds to the UAS. Thus, expression of 
the gene of interest is enabled and directed in a spatiotemporal manner in the 
offspring. Further, the Drosophila genetic crosses can be designed in such a way that 
the survival, appearance and behaviour of the offspring that expresses the mutant 
transgene can be compared to siblings that are not expressing the transgene. 
 The UAS/Gal4 system can be also used to deliver RNAi induced gene silencing. 
RNAi-mediated gene silencing (or RNAi) mimics classical knockout experiments.  
 
 
 
 
 
Figure 5: The UAS/Gal4 expression system for controlling gene expression in 
spatio-temporal tissue specific manner and RNA mediated gene silencing. 
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(A) Tissue-, cell- or stage-specific endogenous enhancer binds to promoter of enhancer trap 
construct to enable Gal4 expression. Gal4 in turns binds to upstream activation sequenes 
(UAS) of the human transgene containing fly line thereby activating human transgene 
expression. (B) Gene silencing- The UAS/Gal4 System drives the expression of the hairpin 
RNA (hpRNA). Dicer prossess these double-stranded RNAs into siRNA, which then direct 
sequence-specific degradation of the target mRNA. (IR- inverted repeat; hpRNA-hairpin RNA; 
siRNA- small interfering RNA) 
 
1.5.2 The rough eye phenotype 
 The compound eye of Drosophila melanogaster is a simple yet a powerful 
experimental platform to decipher a variety of complex biological mechanisms for 
example cell cycle control, cell proliferation, differentiation and apoptosis. Dysfunction 
in cellular pathways, developmental perturbances, loss of retinal neurons by 
overexpressing external disease related transgenes are usually manifested by 
irregularities of the compound eye structure leading to a rough eye phenotype (REP). 
The REP severity correlates with the degree of neuron loss manifesting in eye surface 
disturbances, depigmentation, necrotic spots, fused ommatidia and disordered sensory 
bristles. All these changes can be easily seen using a normal dissecting microscope, 
thus making the REP an ideal phenotypic readout for high throughput modifiers 
screens. 
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2 Aim of the study  
Recent studies suggest TDP-43 as a common entity in many neurodegenerative 
disorders. When this study was initiated, only some basic properties of TDP-43 were 
known. The molecular mechanisms of TDP-43-related neuropathology were largely 
unknown. Based on several in vitro and in vivo studies, both neurotoxic GOF and LOF 
processes have been proposed for TDP-43-related neuropathology. The precise 
impact of missense mutations and/or aggregation of mutant or wild type TDP-43 for 
neuropathology were unclear. To gain entry points to understand TDP-43-mediated 
neuropathology, it was particularly urgent to clarify the relative impact of inherent TDP-
43 protein function and ALS/FTLD-linked TDP-43 mutations on neurotoxicity. 
 In the present study, the aim was (1) to establish and characterise a Drosophila 
model of TDP-43 proteinopathy. To recapitulate the key aspects of pathological, 
biochemical and behavioural phenotypes induced by TDP-43. In addition (2) to 
uncover the relation between structural/functional components of TDP-43 and toxicity. 
The study strongly focused on the clarification of the role of inherent protein function, 
disease-linked missense mutations or truncation/mislocalisation and aggregation on 
TDP-43-mediated neurotoxicity. 
 To identify physical and genetic interactors two screening approaches were 
undertaken. Since TDP-43 is a multifunctional hetergeneous ribonucleoprotein 
predicted to interact with many other proteins, a yeast-2- hybrid screen was conducted 
to search for its physical interactors. In addition an unbiased genome-wide screen was 
conducted in Drosophila to identify modifiers of TDP-43-induced toxicity. This was 
aimed to decipher disease-associated molecular pathways and processes. Both of the 
screening approaches should provide novel insights in (patho) physiological function(s) 
of TDP-43. 
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3 Material and Methods 
3.1 Chemicals, buffers and equipment 
In this section composition of reagents and buffers used in presented study is 
specified.  
Table 2: Chemicals, reagents and buffers used in this study 
Name Specification/Manufacturer 
Acrylamid Acrylamid 2K (30 %) (A0856, 1000) AppliChem, Germany 
APS Ammonumperoxidisulfate ≥ 98 % (3313.1), Roth, Germany 
Bromophenol Blue (A512.1) Roth, Germany 
BSA (K61-017) PAA Laboratories, Austria 
Chloroform Trochlormethane/Chloroform ≥ 98 % p.a. (9592.2), Roth, 
Germany 
Citric acid (1.00244.1000), Merck, Germany 
DAPI (6335.1) Roth, Germany 
DAPI usage solution 10 mg DAPI in 3 ml 100 % EtOH, ad 500 ml PBS, for usage 
dilute 1:10 
DEPC Diethypyrocarbonat (K028.1), Roth, Germany (to treat H2O: 
stir 0.1% DEPC in bidest H2O over night and autoclave) 
DNAse  RQ1 RNAse-free DNAse (M6101), Promega, USA 
Drosophila Ringer Solution  182 mM KCl, 46 mM NaCl, 3 mM CaCl2 x 2 H2O, 10 mM 
Tris, pH 7.2, autoclaved 
DTT 1,4-Ditrhiothreit (6908.1), Roth, Germany 
EDTA ≥ 99 % p.a. (8043.2), Roth, Germany 
Ethanol ≥ 99.8 % p.a. (9065.4), Roth, Germany 
Fast Digest(R) Restriction 
enzymes 
Fermentas, Germany 
Glycerol 99 % (G5516-1L), Sigma, Germany 
Immun-StarTM Immun-StarTM Western C TM Kit (170-5070), Bio-Rad, USA 
  
iQ TM SYBR ® Green Supermix (170-8882), Bio-Rad. USA 
iScript TM cDNA Synthesis Kit (170-8890), BioRad, USA 
Isopropanol 2-Propanol (T910.1), Roth, Germany 
Laemmli buffer (5x) 10 % Glycerol, 2 % SDS, 12.5 % Tris-Cl (0.5 M), ph 6.8, 5 
% β-mercaptoethanol, 0.05 % bromophenol blue 
LR Accelerator (62660) Sigma, USA 
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Mercaptoethanol β-mercaptoethanol (4227.3), Roth, Germany 
Methanol (X948.2) ROTISOLV® HPLC Ultra Gradient Grade, Roth, 
Germany 
MG-132 Calbiochem® (474790) 
NaCl ≥ 95.5 %, p.a., Roth, Germay 
NaH2HPO4 x H2O ≥ 99 % p-a- (1.06342.1000), Merck, Germany 
Nitrocellulose membrane Protran® BA 83 (10 402 396), Whatman®, Germany 
Paraffin 32.3 % Paraffin 42-44 (107150= 32.3 % Paraffin 51-53 
(107157), 32.3% Paraffin 57-60 (107158), all Merck, 
Germany and 32.3 % bees wax (5825.2), Roth, Karlsruhe 
Germany 
Perchloric acid ROTIPURAN® Supra 70 %, (HN51.1) Roth, Germany 
PBS 8 mM Na2HPO4 x H2O, 1.8 mM NaH2HPO4 x H2O and 0.1 M 
NaCl 
PBT 0.14 M NaCk, 6 mM Na2HPO4, 2.7 mM KCl, 1.5 mM 
KH2PO4, 0.05 % Triton 
PFA (4%) 4 % paraformaldehyde (0335.2, Roth, Germany) in PBS 
Protein Assay Kit (500-0116), DC Protein Assay Reagents Package, BioRad, 
USA 
Qiagen RNeasy Mini Kit (74106) Qiagen, Germany 
Rapamycin Alexis (380-004-M005) 
Resolving gel buffer 0.4 % SDS, 1.5 M Tris, pH 8.8  
RIPA Lysis buffer 50 mM Tris, pH 8.0,0.15 M NaCl, 0.1 % SDS, 1.0 % NP-40, 
0.5 % Na-Deoxycholate, 2 mM EDTA, Complete™ 
Protease Inhibitors, p.H 7.4 
RNase Inhibitor RiboLock™ RNase Inhibitor 40 u/µl (E00381), Fermentas, 
Germany 
Running buffer 0.1 M Tris, 1 M Glycine, 0.5 % SDS 
SDS AccuGene 10 % SDS (52324), Cambrex, USA 
SDS gel (12 %) Resolving gel: 1.25 ml resolving gel buffer, 1.75 ml bidest 
H2O 
Sodium acetate Sodium acetate (1.06268.0250, Merck, Germany) 3 M in 
H2O, pH 5.4 
Stacking gel buffer 4 % SDS, 0.25 M Tris, pH 6.8 
Sucrose D (+)-Saccharose ≥ 99.5 % p.a. (4621.1), Roth, Germany 
TBS 25 mM Tris, 140 mM NaCl, pH 7.5 
TBS-T 25 mM Tris, 140 mM NaCl, pH 7.5, 0.05 % Tween 
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TEMED N,N,N´,N´-Tetramethylethylendiamide, (A1148,0100) 
AppliChem, Germany 
Transfer buffer 25 mM Tris, 192 mM glycine and 20 % methanol 
TritonX TritonX 100, Sigma, USA 
Trizol® (9127.1), Trizol® Reagent, Roth, Germany 
Urea Buffer 7M urea, 2M thiourea, 4% CHAPS, 30mM Tris, pH8.5 
Tween  Tween® 20 (9127.1), Roth, Germany 
Vectashield (H 1000) Vectashield mounting medium, Vector, USA 
Xylol Otto Fischer, Germany 
 
Table 3: Softwares and online tools 
Name Application 
Alliance UVItec 15.11 Documentation of Western blots 
Axiovision 4.8.1 Car Zeiss Software for light microscope 
systems 
BioDoc Analyse 2.1 Software for quantification of Western blots 
https://blast.ncbi.nlm.nih.gov Alignments for detailed determination of gene 
homologues between Drosophila 
melanogaster and Homo sapiens. 
GNU Image Manipulation Program (GIMP) 
(Version 2.6.11)  
Image processing, compilation of pictures 
GraphPad Prism Illustration of quantitative data (qPCR, 
longevity etc.) and according statistics 
i-Control 1.6 Measurement of mRNA, protein 
concentration, TECAN, Switzerland 
iQ5 Handling of MyiQ2 real-time cycler and 
documentation of qPCR 
Squencher Handling sequence files and designing 
primers 
Olympus Cell A Documentation of histological, 
immunohistological and cytochemical 
micrographs 
Olympus Cell F Documentation of immunohistochemical 
micrographs 
Homologene: 
http://www.ncbi.nlm.nih.gov/homologene 
Determination of homologues between 
Drosophila melanogaster and Homo sapiens 
Flybase Information about transgenic lines used 
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http://www.flybase.org/ 
VDRC 
http://www.stockcenter.vdrc.at/control/main 
Acquisition of RNAi lines  
Bloomington stock center 
http://www.fly.bio.indiana.edu/ 
Acquisition of classical alleles, misexpression 
lines and alternative lines 
 
Table 4: Equipment 
Name/Specification Manufacturer 
Microtom HM 360 Thermo Scientific, Germany 
Zoom stereo microscope SZX 10 with ring light S80-
55 RL and camera SC30 
Olympus, Germany 
Research microscope BX51 with light source X-
Cite® 120 Q and camera DP72 
Olympus, Germany 
Tissue homogenizer Speedmill P12 Analytik Jena AG, Germany 
MyiQ2 two colour realtime cycler Bio-Rad, Germany 
Multimode microplate reade Infinite® TECAN infinite M200, Tecan, 
Switzerland 
Chemiluminscence documentation system Alliance 
LD4.77.WL.Auto 
Biometra, Germany 
 
3.2 Transgenic Drosophila strains and fly keeping conditions 
All fly stocks were maintained on standard cornmeal-yeast agar-based fly food at 18° 
C and experiments were performed at 25°C, 29°C or 18°C notified with experiments 
and a relative humidity of at least 50% was maintained. All adult-onset expression, Gal 
80-expressing flies were shifted from permissive temperature at 20°C to restrictive 
temperature of 18°C. The site-directed and random-inserted UAS:TDP-43 transgenic 
lines were generated by germline transmission (BestGene).StrainPBac {yellow[+]-attP-
3B}VK00002 (cytological region 28E7 on 2nd chromosome; strain identifier at 
BestGene: 9723) was used to generate the site-directed insertions of different TDP-43 
variants.  
 
 
 
 
 
CHAPTER 3 – MATERIAL AND METHODS   19 
Table 5:Generated Transgenic Drosophila melanogaster Strains used in present 
study 
Transgenes Genotypes Feature 
TDP-43WT w/Y;UAS::TDP-43WT/CyO Full length (FL) TDP-43  
TDP-43ΔNLS w/Y;UAS::TDP-
43ΔNLS/CyO 
FL-TDP-43 lacking a functional nuclear 
localisation signal 
TDP-43CTF w/Y;UAS::TDP-43CTF/CyO C-terminal fragment of TDP-43 modeled after 
major form found in cytosolic aggregates of 
ALS/FTLD Patients. 
TDP-43FFLL  w/Y;UAS::TDP-
43FFLL/CyO 
FL-TDP-43 lacking inherent RNA-binding 
function 
TDP-43A315T w/Y;UAS::TDP-
43A315T/CyO 
FL-TDP-43 harbouring a disease linked point 
mutation A315T 
TDP-43A380T w/Y;UAS::TDP-
43A380T/CyO 
FL-TDP-43 harbouring a disease linked point 
mutation A380T 
TDP-43G348C  w/Y;UAS::TDP-
43G348C/CyO 
FL-TDP-43 harbouring a disease linked point 
mutation G348C 
TDP-43G287S w/Y;UAS::TDP-
43G287S/CyO 
FL-TDP-43 harbouring a disease linked point 
mutation G287S 
TDP-43N390D  w/Y;UAS::TDP-
43N390D/CyO 
FL-TDP-43 harbouring a disease linked point 
mutation N390D 
TDP-43WT:GFP  GFP-tagged FL-TDP-43WT, 11 lines with 
variable expression strength. 
TDP-
43ΔNLS:GFP 
 GFP-tagged full length TDP-43ΔNLS lacking 
functional nuclear localisation signal with 
variable expression strength (16 lines) 
TDP-43CTF:GFP  GFP-tagged C-terminal fragment of TDP-43 16 
lines with variable expression strength (11 
lines) 
GMR>TDP-
43WT 
 (GT) 
 Retinal expression of TDP-43 resulting in REP 
for modifier screening 
elav>TDP-43  Pan-neural expression of TDP-43 (untagged 
variant) 
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Table 6: Other Drosophila melanogaster strains used in the study 
Transgenic 
line 
Genotype Feature  Origin 
Oregon R wild-type  Bloomington #5 
GMR-Gal4 w[*];P{w[+mC]=GAL4-
ninaE.GMR}12 
Eye specific driver  Bloomington 
#1104 
elavC155-Gal4 P{w[+mW.hs]=GawB}elav[C155] Pan-neural driver  Bloomington 
#458 
D42-Gal4    w[*];;P{w[mW.hs]=GawB}D42/TM
3,sb[1],Ser[1] 
 
Motor-neuron driver  Bloomington 
#8443 
Actin5C-Gal4 
 
y[1]w[*];P{w[+mC]=Act5C-
GAL4}25F01/CyO,y[+] 
 
Ubiquitous driver  Bloomington 
#4414 
MHC-Gal4 w[*],P{w[+]=MHC-Gal4} Muscle specific driver  Gift from Gerd 
Vorbrueggen 
Repo-Gal4 w[118];P{w[+m*]=GAL4}repo/T
M3,sb[1] 
Glia specific driver  Bloomington 
#7415 
DAG32-Gal4 w[*];;P{w[+]DaG32-Gal4} Ubiquitous driver  Gift from Doris 
Brendtrup 
Elav-tub-
Gal80ts     
 
P{w[+mW.hs]=GawB}elav[C155];
P{w[+mC]=tubP- GAL80[ts]}20   
 
Temperature sensitve 
pan-neural driver  
Created by 
Malte Butzlaff 
(original Gal80 
stock: 
Bloomington 
#7019 
GFP w[*;P{w[+mC]=UAS-eGFP}/Cyo GFP transgene Created by Peter 
Karsten via 
bestgene 
Sco/CyO y[1] w[*];Sco/CyO 2nd chromosomal 
marker 
Bloomington 
#2555 
S6K-WT w[1118]; P{w[+mC]=UAS-
S6k.M}2/CyO 
S6K Wild type Bloomington # 
6910 
S6K-TE w[1118]; P{w[+mC]=UAS-
S6k.TE}2 
 
Phosphomimetic, 
constitutively active 
form of S6K 
Bloomington 
#6912 
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S6K-STDE w[1118]; P{w[+mC]=UAS-
S6k.STDE}3 
 
Phosphomimetic, 
constitutively active 
form of S6K 
Bloomington 
#6913 
S6K-STDETE w[1118]; P{w[+mC]=UAS-
S6k.STDETE}2 
 
Phosphomimetic, 
constitutively active 
form of S6K 
Bloomington 
#6914 
4E-BP w[*]; P{w[+mC]=UAS-eIF-4E.R}2 
 
eukaryotic initiation 
factor (elf4E)-binding 
protein (4E-BP) 
Bloomington 
#8650 
4E-BP w[1118]; P{w[+mC]=UAS-eIF-
4E.A}26/CyO 
 
eukaryotic initiation 
factor (elf 4E)-binding 
protein (4E-BP) 
Bloomington 
#8710 
4E-BP mutant w[1118]; P{w[+mC]=UAS-eIF-
4E.S251A}8 
 
Non phosphorytable 
4E-BP 
Bloomington 
#8711 
TBPH-RNAi P{TRiP.HM05194}attP2  TBPH- shRNA Bloomington # 
29517 
White-RNAi w[1118];;P{GD14981}v30033 White-shRNA VDRC #v30033 
CL1-GFP w[*]; P{w[+]=UAS-CL1:GFP A fusion protein 
composed of CL1 (a 
degradon sequence) 
and GFP. A 
fluorescent reporter 
of GFP function 
gift from 
J.P.Taylor [81] 
DTS-7 GMR;DTS7 Atemperature 
sensitive, dominant 
mutant of the B2 
subunit of 
proteasome. 
gift from 
J.P.Taylor [81] 
3.2.1 The UAS/Gal4 expression system and Mating Procedure  
The UAS/Gal4 system is used in Drosophila to direct expression of any transgene in 
cell, tissue or development stage of interest. This is achieved using two different lines; 
one line contains Gal4 coding sequences inserted in enhancer region of specific genes 
termed as driver line. Gal4 specifically binds to promoter elements known as upstream 
activating sequence (UAS), thus activating expression of a downstream target gene. 
Thus the second line harbours the silent target flanked by UAS site, termed as UAS 
line. Upon crossbreeding the both lines the target gene will be expressed, in spatio-
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temporal manner. The TDP-43 transgenic flies were crossbred with driver strains at 
25°C otherwise noted 
In the presented work, we used UAS/Gal4 system with an additional transcriptional 
repressor Gal80 to achieve adult onset of expression. Like Gal4, Gal80 is also derived 
from yeast and inhibits Gal4 DNA-binding activity. By using transgenic flies expressing 
a temperature sensitive Gal80 expression, transgene expression can be regulated by 
temperature switch. In the transgenic flies breeding at 18°C Gal4-dependent 
transcription is silent, as Gal80 binds to Gal4 and inhibits Gal4 binding to UAS site, 
however at 29°C relieves this repression and expression is achieved at desired 
experimental time point.  
 . 
 
Figure 6: The UAS/Gal4 system and achieving adult onset expression with Gal80 
extension  
UAS/Gal4 dual activation provides a wide variety spatio-temporal expression onset. The driver 
line harbours Gal4 under control of endogenous promoter element. The UAS line contains the 
transgenic construct flanked by upstream activating sequences (UAS). The UAS line remains 
silent until crossed to driver line. The driver provides the Gal4 transcription factor to direct 
expression of the gene of interest. Gal80 binds to DNA-binding site of Gal4 thus repressing 
Gal4-dependent gene expression. The temperature shift to 29°C relieves the repression by 
Gal80, thus facilitating expression. 
3.2.2 Longevity assays 
Life span evaluation was performed using male flies with the respective genotype 
raised and selected at 18°C (adult onset system) or 25°C grouped into vial upto 
maximum 20 flies. Longevity assays were conducted at 25°C for normal UAS/Gal4 
strain, lines containing Gal80 were shifted to permissive temperature of 29°C for the 
onset of transgene expression. Flies were transferred to fresh food every 2nd or 3rd 
day and death events were observed daily. A minimum of 60 flies per genotype were 
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scored for every experiment. GraphPad prism  was used for Kaplan-Meyer plotting and 
statistical analysis, featuring Log-Rank test for comparison of  longevity curves. 
3.2.3 Climbing Analyses 
A motor neuron specific driver (D42-Gal4) was used to express of TDP-43 transgenes. 
Flies were raised at 25°C, male flies were collected (0-48 hours post hatching) and 
shifted to 29°C. Individual flies were tested three times per time point (1, 10, 20 days 
after temperature shift) for negative geotaxis (ability to climb 8 cm in 10 seconds). At 
least a total of 60 flies was used per time point and genotype. Statistical analysis was 
performed using GraphPad Prism. 
3.2.4 Screening procedure and rough eye phenotype modification 
In this study a genome wide screen for toxicity modifiers was performed. The GMR-
Gal4 was recombined with TDP-43WT:GFP#14 to generate a screening stock with a 
robust Rough eye phenotype (REP) i.e GMR>TDP-43WT henceforth referred as “GT”. 
The Bloomington deficiency kit was utilised for primary screening purposes. 
GMR>TDP-43WT virgins were crossed to flies carrying defined autosomal deficiencies 
to obtain offsprings with required genotype. These offspring were analysed for change 
in the severity of eye degeneration. Deficiencies causing a synthetic haploinsufficiency 
or an obvious enhancement or suppression were crossed thrice to recapitulate the 
effect. Further to identify and quantify subtle effects (where applicable), a 10 point 
scoring system was devised. Eyes were examined and scored according to the 
following parameters: (i) Absence or abnormal orientation of supernumerary 
interommatidial bristles below 50% (1 point) or more than 50% (2 points), (ii) Black 
lesions (more than three small or one large Black lesion (2 points), less then 3 spots (1 
point), (iii) Retinal collapse (2 points) or eye surface disturbance (1 point), (iv) Fusion 
of ommatidia or disorganization of ommatidial array below 50% (1 point) or greater 
than 50% (2 points), (v) Loss of pigmentation below 50% (1 point) or above 50% (2 
points) resulting in pale red or white colour of the eye. 
Deleted segments of candidate deficiencies were subdivided in smaller intervals using 
additional deficiencies, if available. Further expression of flies expressing another 
neurodegenerative protein Aβ42 [256] also results in REP, deficiencies showing similar 
results for both TDP-43 and Aβ42 were not considered specific for TDP-43 induced 
toxicity, hence not included in further analysis. The used chromosomal deficiencies 
obviously delete several genes. In order to identify the single genes responsible for 
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identified genetic interaction, we used overlapping deficiencies (if available) to reduce 
the number of candidate genes followed by single gene analysis. For single gene 
analysis, we utilised RNAi-mediated gene silencing (UAS-RNAi lines). The RNAi lines 
were obtained from Vienna Drosophila RNAi center (VDRC). These lines harbour 
random insertion of transgenes expressing inverted repeats under control of the binary 
UAS/Gal4 system. The inverted repeats code for shRNAs targeting single Drosophila 
genes.  These RNAi lines were already tested with GMR-Gal4 driver line (control) and 
the lines that had modulating effect in GMR-Gal4 REP were excluded [82]. As our 
analysis aimed to identify modifiers of human disease, we restricted to our analysis to 
fly genes displaying a human orthologue. 
3.2.5 Drug administration/pharmacological treatment 
MG-132 is a specific proteasome inhibitor; it reduces the degradation of ubiquitin-
conjugated proteins. We used MG-132 to study the effect of proteasomal inhibition with 
respect to TDP-43 clearance. 
MG-132 (Cat no-474790, Calbiochem) was first dissolved in DMSO and the solution 
was then added to cooled cornmeal agar fly food (50 μM, 2% DMSO, final 
concenteration in food). The food was then dispensed into empty food vials and 
allowed to solidify. Food was kept in dark at 4°C.  
As another drug which was tested Rapamycin, a drug that inhibits TOR pathway and 
proved to be beneficial in other neurodegenerative diseases. Life span extension is 
mediated through translation changes and autophagy [83]. We used Rapamycin to 
investigate any possible effect on TDP-43 and autophagy. Rapamycin stock solution of 
1 mM in DMSO was prepared and added to instant food to the final concenteration 2 
μM,  
Fresh vials were prepared every second day for chemically substituted food. 
3.3 Protein biochemistry 
3.3.1 Head lysate preparation 
 Fly heads were dissected and lysed in RIPA lysis buffer. For fly tissue 
homogenisation, fly heads were collected in tubes filled with few ceramic beads using 
mechanic disruption of tissue (speedmill P12 Analytic Jena AG, Germany). Lysates of 
homogenised heads were cleared by centrifugation at 13.3 g for 10 minutes at 4°C. 
Supernatent was collected in fresh eppendorf tubes and stored at 20°C or 80°C.  
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For serial extraction of soluble and insoluble protein fractions, the following protocol 
was used. 50 fly heads were homogenised in 100 μL RIPA buffer and incubated for 1 
hour at 4°C on a electric rocker. After incubation, lysates were centrifuged at 13.3 g for 
20 minutes at 4°C, supernatent was collected as RIPA or soluble fraction, pellet was 
washed again with 50 μl of RIPA buffer and centrifuged again (13.3 g, 20 minutes at  
4 °C) and the supernatent was  pooled with the soluble fraction. 60 μl of urea buffer 
was added to the pellet and homogenised again and centrifuged at 13.3 g for 30 
minutes and supernatent was collected as urea/ insoluble fraction.  
3.3.2  SDS-polyacrylamide-gel-electrophoresis and Western blot  
Protein lysates were separated electrophoretically in 12 % SDS-polyacrylamide gels. 
Prior to electrophoresis, all samples were mixed with sample loading buffer and boiled 
for 5 min at 95 %. Electrophoresis was performed for 80-100 minutes at 100-120 V 
using running buffer. For the first 10 minutes voltage was set to 120 V for proper 
stacking of samples, later voltage was set to 100 V for better resolution of bands. 
Heads of flies were dissected and homogenised in RIPA buffer. Lysates were 
separated on 12% gel by SDS-PAGE. Proteins were transferred to nitrocellulose 
membraness. Membrane were blocked with 5% (w/v) skimed milk Tris buffered saline 
containing 0.1% Tween 20.  Primary antibodies used to detect protein expression are 
listed below (Table 7). Secondary HRP-coupled antibodies (1:10,000, Amersham) were 
used for chemiluminiscence detection (Immuno-StarTM, Western CTM 
Chemiluminescent Kit, BioRad). For filter retardation assay, equal protein amounts (15 
μg) of head lysates were adjusted to 2% SDS and 50 mM dithiothreitol followed by 
heating to 95°C for 3 minutes. Using a dot blot filtration unit, the resulting solutions 
were filtered through a 0.2 μm nitrocellulose membrane (Whatman) previously 
equilibrated with 0.1% SDS in TBS and afterwards washed in TBS-T. Membranes 
were further processed for protein immunodetection as described previously by 
blocking and probing with primary and secondary antibodies followed by 
documentation. 
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Table 7: Primary antibodies used in this study 
Antibody Company Epitope Dilution 
α HSMNP1 Santa Cruz 
Biotechnology 
Peptide mapping within an 
internal region of HSMNP1 
of human origin 
1:1000 
α syntaxin DSHB 8C3/D.melanogaster  
syntaxin 
1:2500 
α synapsin DSHB 3C11(anti SYNORF1) 1:2500 
α TDP-43 Proteintech N-term of TDP-43 1:1000 
α GFP Roche  Mouse IgGclones (7.1, 
13.1) 
1:1000 
α pTDP-43 Gift from 
M.Neumann,Tuebingen 
SER409/410 1:250 
α Ubiquitin Dako ubiquitin  1:300 
 
3.4 Quantitative PCR analysis. 
Total RNA from flies was isolated using Trizol (Invitrogen) followed by chloroform-
ethanol precipitation and purified using Qiagen RNaeasy kit following the  
manufacturer’s protocol. For qRT-PCR 1μg total RNA was reverse transcribed using 
high fidelity cDNA synthesis kit (Roche). qRT-PCR from cDNA samples was conducted 
using the iQTMSYBR® Green Supermix and MyiQ2 real-time cycler with iQ5 software.  
qPCR cycle parameters used were: 
Cycle1: (1X) 
Step1:                 96°C for 3 mins 
 
Cycle 2: (40X) 
Step 1:                96°C for 30 seconds 
Step 2:                60°C for 45 seconds 
Step 3:                72°C for 45 seconds 
With data collection and real-time analysis enabled. 
 
Cycle 3: (1X) 
Step 1:                 96°C for 10 seconds 
Step 2:                 55°C for 30 seconds 
 
Cycle 4: (42X) 
Step 1:                 55-96 °C for 30 seconds 
Increase set point temperature after cycle 2 by 1°C,  
Melt curve data collection and analysis enabled. 
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 Amplification efficiencies of targets and references were determined and used for 
further calculations of normalized relative (Delta Delta C(T)) expression levels 
according to One-way  ANOVA with Bonferroni correction was used for statistical 
analysis (GraphPad Prism). Primers used for qRT-PCR amplification were 
 
Primers Primer sequence (5’-3’) 
Actin-5C_for CACACCGTGCCCATCTACGAGG 
 
Actin -5C_rev CTTCTGCATACGGTCGGCGATGC 
 
TDP-43_for ACTGAGGATGAGCTGCGGGAGTTC 
 
TDP-43 _rev CAAAGAGACTGCGCAATCTGATCATCTG 
 
TBPH_for GGAAGGGGCCGAATAACCCGAAC 
 
TBPH_rev 
 
CACACATCATTGGGTGACAGGCACC 
 
3.5 Statistical analysis 
All statistical analysis and data plotting was performed using GraphPad Prism 
software. Statistical tests applied are mentioned with the respective experiments in the 
results section. 
3.6 Yeast-2-hybrid screen  
A yeast-2-hybrid screen is a well-established tool to identify and study novel or known 
protein-protein interactions utilizing yeast Saccharomyces cerevisiae and its 
transcriptional factor Gal4 properties. We used MatchmakerTM 2 Hybrid System from 
Clontech. In principle, a bait protein is expressed as a fusion to the Gal4 DNA-binding 
domain and screening library of prey proteins are expressed as fusions to the Gal-4 
activation domain. When bait and library (prey) fusion proteins interact, the DNA-BD 
and AD are brought into proximity to activate transcription of reporter genes. This 
technology can be used to identify novel protein interactions, confirm suspected 
interactions and define interacting domains. All experiments were done according to 
manufacturer’s protocol. A human brain cDNA library was screened for TDP-43ΔNLS 
interactors. The cDNA library was pretransformed into S.cereviseae Y187 and was 
mated with S.cereviseae (AH109) strain expressing TDP-43ΔNLS as bait. 
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4 Results 
 When the presented work was started, there were no TDP-43 animal models 
[84] available and most of the information about TDP-43 function was derived from cell 
culture based assays. During this work, we established one of the first in vivo models 
for TDP-43 proteinopathy. Drosophila melanogaster is an established model to study 
neurodgenerative diseases [78, 85, 86]. We generated trangenic flies capable of 
expressing human TDP-43. These flies were subsequently analysed with regard to 
GOF phenotypes. In addition, a yeast-2-hybrid screen to identify physical interactors of 
TDP-43 was performed.  
The presented study was designed by Aaron Voigt and Kavita Kaur. All experiments 
were conducted by Kavita Kaur (otherwise noted) under the supervision of Aaron 
Voigt.  
 The plasmids used to generate TDP-43 transgenic flies were cloned by Aaron 
Voigt and Peter Karsten. Injection of the plasmids and generation of the 
transgenic flies was facilitated using the Drosophila embryo injection service 
(BestGene, USA). 
 TDP-43 transgenic flies were characterised and tested by Kavita Kaur. The 
viability assays, subcellular localisation assays, longevity assays, climbing 
assays, protein biochemistry assays, RT-PCRs were performed and analysed 
by Kavita Kaur. This data is part of a publication (PLoS One, August 2010 
doi:10.1371/journal.pone.0012247). 
 Flies for histological analysis were prepared by Kavita Kaur. Fly histology was 
performed by Sabine Hamm. Histological sections were analyzed and 
interpreted by Kavita Kaur. 
 Electrophysiological assay on neuromuscular junction was performed by Tanja 
A. Godenschwege at Florida Atlantic University. 
 Chick experiment was performed by David Herhloz in the lab of Till Marquardt at 
ENI, Goettigen. This data is part of the above-mentioned publication. 
 The modifier screen for TDP-43 induced toxicity was performed and analysed 
by Kavita Kaur. 
 Yeast-2-hybrid screen was performed by Kavita Kaur.  
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The final results were evaluated, analysed and discussed by Kavita Kaur and Aaron 
Voigt. 
4.1 Characterisation of TDP-43 proteinopathy in Drosophila 
4.1.1 GFP-tagged TDP-43 transgenic lines exhibiting Variable expression  
 To study human TDP-43 in vivo, various transgenic lines were generated by Dr. 
A.Voigt. Transgenic flies were created by random insertions of the respective 
transgenes for UAS/Gal4-based overexpression of GFP-tagged TDP-43. Three 
different variants of TDP-43 were generated: TDP-43WT-GFP, TDP-43ΔNLS-GFP and 
TDP-43CTF-GFP. TDP-43WT-GFP represented human wild type full length TDP-43. 
TDP-43ΔNLS-GFP lacks the nuclear localisation signal thereby mimicking 
cytoplasmically mislocalised full-length TDP-43. TDP-43CTF-GFP is a synthetic protein 
modelling the after C-terminally truncated fragment found in cytosolic aggregates of 
ALS/FTLD-U patients. GFP-tagged variants allowed to visualise TDP-43:GFP (green) 
directly in vivo. All TDP-43 transgenic lines were tested and characterised for various 
preliminary parameters, for example TDP-43 protein expression level, viability and 
longevity. Several lines were then selected and subjected to final experiments for an in 
depth study of TDP-43 induced toxicity and neurodegeneration. Western blot analysis 
was performed to detect TDP-43 protein expression of GFP-tagged transgenic lines. 
Based on protein expression levels we annotated and selected weak, moderate and 
high expression lines for further assays (Figure 7) 
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Figure 7: Random insertions and differential expression of GFP-tagged TDP-43 
transgenic lines. 
(A) Cartoon showing the domain composition of TDP-43 (top). Location of the nuclear 
localisation signal (NLS), the two RNA recognition motives (RRM1, RRM2) and the location of 
the C-terminal domain (CTD) are indicated. Schematic representation of proteins coded by the 
three different constructs used to generate transgenic flies. The number of independent 
transgenes obtained is indicated. (i) TDP-43WT represents the human full-length protein. In 
TDP-43ΔNLS (ii) the nuclear localisation signal is mutated to achieve cytoplamic mislocalisation. 
TDP-43CTF (iii) is modelling the truncated fragment, which is the major component of inclusions 
found in ALS patients. (B) Exemplary Western blot showing differential pan-neural TDP-43WT 
expression levels of GFP tagged TDP-43 variants in adult Drosophilae. TDP-43 expression 
was visualised using anti-GFP antibody. Syntaxin served as loading control. 
 
 All transgenic lines were tested for viability after ubiquitous expression (DaG32-
Gal4) and pan-neural expression (elav-Gal4). Ubiquitous expression of TDP-43WT:GFP 
and TDP-43∆NLS:GFP almost exclusively caused lethality. However ubiquitous 
expression of TDP-43CTF:GFP never caused lethality (see Table 8). Pan-neural 
expression of different TDP-43:GFP variants never caused lethality. Only the 
transgenic line TDP-43WT:GFP#14 gave no viable offspring when crossed to the pan-
neural driver elav-Gal4. However, viable offsprings were obtained when this line was 
crossed to a muscle specific driver (MHC-Gal4) or glia specific driver (repo-Gal4). This 
strongly suggests that the effects after pan-neural expression of TDP-43WT caused 
neurotoxicity, rather than general toxicity (Table 8).  
 
Table 8: Viability assay of TDP-43:GFP variants using various driver lines. 
TDP-43 transgene Gal4-driver lines used 
Random insertions elav-Gal4 (pan-neural) 
DaG32-Gal4  
(weak ubiquitous expression) 
TDP-43WT:GFP 
(11 Lines) 
10 viable, 1 lethal (line #14) 1 viable, 10 lethal 
TDP-43ΔNLS:GFP 
(16 Lines) 
15 viable, 1 lethal 1 viable, 15 lethal 
TDP-43CTF:GFP 
(11 Lines) 
11 viable, 0 lethal 11 viable, 0 lethal 
 
TDP-43 highest expression 
transgene 
Gal4-driver lines used 
TDP-43WT-GFP#14 eyeless-Gal4 (eye) repo-Gal4 (glia) 
 viable viable 
TDP-43WT-GFP#14 MHC-Gal4 (muscle) 
Actin5C-Gal4  
(strong ubiquitous 
expression) 
   viable Lethal 
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4.1.2 Subcellular localisation of TDP-43:GFP tagged variants 
In Drosophila larvae, photoreceptors and their nuclei are located in the eye imaginal 
disc, from where photoreceptors project via the optic nerve into the optic lobes of the 
brain [87]. Accordingly, the visual system can be used to analyse the cellular 
distribution of the TDP-43:GFP variants. Expression of all three TDP-43 variants in 
photoreceptors (GMR-Gal4) resulted in a robust accumulation of GFP signal in 
targeted cells of the eye disc. As expected, larvae expressing TDP-43WT:GFP did not 
display any GFP signal in photoreceptor projections (Figure 8). The localisation of the 
GFP signal was restricted to the nuclei of the eye disc. In contrast, robust GFP staining 
was detected in photoreceptor projections in TDP-43∆NLS:GFP and TDP-43CTF:GFP 
expressing larvae. This indicates an at least partial cytoplasmic localisation of the 
∆NLS and CTF variants. Similarly cellular distribution can also be visualised in non- 
neuronal cells of salivary glands. We used this readout to analyse the subcellular 
distribution of our non-GFP tagged TDP-43 variants (see Figure 15). 
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Figure 8:  Subcellular localisation of TDP-43: GFP variants in Drosophila.  
Cellular distribution of the different TDP-43 variants was tested in non-neuronal cells of the 
salivary glands or the optic lobe derived from of L3 larvae. (A) GFP fluorescence analysis 
revealed that TDP-43WT:GFP localised exclusively in the nucleus of salivary glands and was 
absent from photoreceptor projection into the optic lobe. (B) In contrast TDP-43∆NLS:GFP was 
absent from the nucleus and localised to the cytoplasm in salivary glands and photoreceptors. 
(C) TDP-43CTF:GFP showed a strong cytoplasmic as well as a nuclear localisation in both cell 
types. Scale bar indicates 100 μm. [41] 
 
 
Preliminary analysis on GFP-tagged TDP-43 variants raised essential insights about 
their behaviour in vivo. All GFP tagged variants localised as expected and TDP-43WT 
was more toxic as compared to TDP-43ΔNLS or TDP-43CTF. However, random 
integration is not ideal for comparative analysis. Position-effects variegation 
complicates the analysis of transgenes and renders precise comparative analyses 
nearly impossible [88]. Furthermore, there could be possible interference from protein 
tag fusions with GFP. 
 To circumvent these caveats and precisely compare TDP-43 variants; we used 
untagged TDP-43 and achieved equalised protein expression levels, by the generation 
of site directed transgenes (see 4.2).  
4.1.3 Expressing TDP-43 in eyes results in rough eye phenotype 
 The compound eye is a superficial structure, which can be easily observed by 
light microscopy. It was noticed that pan-neural expression of TDP-43 by the 
transgenic line TDP-43WT:GFP#14 (short TDP-43WT#14) caused lethality. Accordingly, 
this line was chosen for further analysis. Eye specific (GMR-Gal4) expression of TDP-
43WT#14 (GMR>TDP-43WT#14 or GT) starts in the eye imaginal disc of third instar 
larvae. TDP-43 expression in GT larvae was analysed indirectly by GFP visualisation 
and by detecting the protein directly with TDP-43-specific antibodies in Western blot 
analysis (Figure 9).  
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Figure 9: Schematic representation of eye disc expressing TDP-43WT:GFP 
(A) Diagram of a Drosophila imaginal eye disc (IED) depicting the moving front of the 
differentiating cells known as morphogenetic furrow (MF), indicated by the vertical dashed line. 
This line separates the undifferentiated cells (left) from post-mitotic neuronal progenitors 
(PMN). (B) Eye discs derived from a GMR>TDP-43:GFP (GT) larvae. GFP signal marks TDP-
43 expressing cells posterior of MF. (C) Western blot shows TDP-43 expression which is 
absent in driver (GMR) only control. TARDBP antibody was used to visualise TDP-43. 
Syntaxin served as loading control. 
 
Adult GT flies showed abnormal eye morphology with alteration in the otherwise 
stereotypic arrangement of ommatidia resulting in a so-called rough eye phenotype 
(REP). In addition, a progressive depigmentation of the eye during ageing was 
observed. REPs usually correlate with degeneration of underlying photoreceptors. To 
clarify this issue, adult eyes were sectioned and eye histology was analysed. An 
almost complete loss of rhabodomere structure (not shown) and a strongly reduced 
retinal depth (Figure 10) was observed. 
CHAPTER 4 – RESULTS    34 
 
Figure 10: Induction of a rough eye phenotype by TDP-43 expression.  
Comparison of eyes/eye structures of control flies (A-D) or from GT flies (E-H). Whereas driver 
only control (GMR) show no depigmentation, obvious depigmentation is observed in light 
micrographs of GT flies (A, E). Scanning electron microscopy (B, C, F, G) revealed strong 
alterations of external eye surface (bristle loss and fusion of omatidia) in GT flies (F, G) 
compared to controls (B, C). Toluidine blue stained retina sections showed reduced retinal 
depth and disturbed arrangement of photoreceptors in GT flies, but not in controls (compare 
D,H). Eyes are oriented anterior - left and dorsal - up.  
4.1.4 Pan-neural TDP-43 expression causes neurodegeneration. 
 TDP-43 overexpression in the fly eye leads to degeneration of photoreceptors 
and age-dependent depigmentation (Figure 10). This strongly suggests that TDP-43 
induces progressive degeneration in neuronal cells, like photoreceptors. Driving pan-
neural expression of TDP-43WT (elav>TDP-43WT#14) caused lethality (Table 8). To 
obtain adult flies for analysis, the “adult onset expression system” (see material and 
methods, Figure 6) was used. This system utilises a temperature sensitive Gal4 
antagonist, called Gal80[ts]. At restrictive temperature of 18°C, Gal80[ts] efficiently 
antagonises Gal4-binding to UAS sequences. Shifting to the permissive temperature of 
29°C, the temperature sensitive Gal80[ts] unfolds and fails to antagonise Gal4. As a 
consequence, Gal4 efficiently activates expression of UAS-dependent sequences. 
Moreover, Gal80[ts] is constantly produced in these flies. Accordingly, this system 
allows to switch on and off expression by shifting flies to permissive or restrictive 
temperatures.  
To test the hypothesis of TDP-43 inducing age-dependent neurodegeneration, the   
brain sections of flies with adult onset pan-neural expression of TDP-43WT were 
CHAPTER 4 – RESULTS    35 
analysed. One-day post induction, brains from TDP-43 expressing flies were 
indiscernible from controls. However, six days post induction, flies with TDP-43 
expression displayed vacuoles in the brain, not observed in age matched controls 
(Figure 11). In flies, appearance of vacuoles in the brain is generally linked to 
neurodegeneration [89, 90]. Thus it was assumed that the observed vacuolisation in 
brains upon TDP-43 expression correlates with neuronal decline.  
 
Figure 11: Age-dependent progressive degeneration of fly brain after TDP-43WT 
over-expression. 
Optic lobe sections of flies derived from flies one or six days after shifting from restrictive to 
permissive condition. At one day post induction, flies with pan-neural expression of TDP-43 are 
indiscernible from controls (driver only) (compare A and C). However, six days post induction, 
TDP-43 expressing flies showed vacuolisation of the lobe (arrows) not observed in age 
matched controls (compare B and D). elav;Gal80ts  control(A, C) and elav;Gal80ts/TDP-
43WT:GFP#14 (B, D). 
4.1.5 Expressing TDP-43 in muscles leads to muscle loss  
TDP-43 inclusions are mainly found in neurons, glial and muscle cells [42]. A recent 
study in mice showed that overexpression of TDP-43 in skeletal muscles leads to 
muscle loss [91]. Thus the effect of TDP-43 expression driven by MHC-Gal4 in 
muscles was analysed. Although muscle specific expression of TDP-43 did not result 
in lethality (Table 8) paralysis followed by early death in flies with muscle specific 
expression of TDP-43 was observed . Detailed analysis showed that muscle specific 
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expression of TDP-43WT:GFP resulted in partial eclosion failure. Surviving flies, which 
could eclose, developed a dropped/ clapped wings phenotype and paralysis within 
three to five days which was followed by death after additional three to five days post 
eclosion. The dropped/ clapped wing phenotype is known to arise after degeneration of 
motor neurons and/ or muscle tissue [92]. Therefore, histological sections of fly 
thoracic muscles were analysed. Compared to driver only control, flies with muscle 
specific expression of TDP-43 showed prominent vacuolisation of the muscle tissue 
(Figure 12:). 
 
Figure 12: TDP-43WT over-expression leads to muscle loss. 
Shown are toluidine blue stained sections of thoracic muscles. (A) Intact flight muscles were 
observed in controls (MHC-Gal4 driver only), whereas (B) TDP-43 expression in muscles 
caused vacuolisation (asterisk). MHC; TDP-43WT:GFP. Scale bar represents 50 µm. 
4.1.6 TDP-43 toxicity is dose-dependent 
The generated random inserted GFP-tagged TDP-43 transgenic fly lines were 
expected to differ significantly in TDP-43 expression levels. Moreover, the expression 
of wild type TDP-43 exerts toxic effects in flies was already shown. Thus it was asked 
whether there is a correlation between TDP-43 expression level and longevity. After 
determining the expression levels of all GFP-tagged TDP-43 transgenes, two TDP-
43WT:GFP lines, TDP-43WT:GFP#10 and TDP-43WT:GFP#16, mediating low and 
comparativly  high expression, respectively (Figure 13 A) were selected. To assay 
longevity, flies with pan-neural expression of TDP-43 were used. The flies with 
stronger TDP-43:GFP expression, displayed earlier lethality as compared to the flies 
with weaker TDP-43 expression. This indicates that the toxicity induced by pan-neural 
expression of TDP-43 is dose-dependent. 
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In contrast to TDP-43WT:GFP and TDP-43∆NLS:GFP, it was found that expression of 
TDP-43CTF:GFP did not induce lethality with any of the Gal4-driver used (Table 6). This 
can be only explained by low expression levels of all TDP-43CTF:GFP transgenic lines 
or by the fact that TDP-43CTF:GFP excerts no or only very low toxicity. To address this 
question, we included one GFP-tagged TDP-43CTF transgene with high expression 
level in our analysis. Although the TDP-43CTF:GFP line showed higher expression 
levels compared to both TDP-43WT lines, there was no toxicity observed in longevity 
analysis. This suggest that even high expression levels of TDP-43CTF do not cause 
toxicity in flies. 
 
Figure 13: Pan-neural expression of TDP-43WT dose-dependently causes 
lethality.  
(A) Head lysates derived from flies with pan-neural expression of indicated TDP-43:GFP 
transgenes were subjected to Western blot analysis. TDP-43WT:GFP line #16 displayed 
comparatively stronger expression than line #10. Comparing TDP-43WT:GFP#10 with TDP-
43CTF:GFP#14 showed stronger expression of the TDP-43CTF transgene. Syntaxin served as 
loading control. (B) Survival curves derived from longevity analysis of indicated transgenes. 
Pan-neural induction of TDP-43WT:GFP#16 caused an earlier mortality as compared to TDP-
43WT:GFP#10. Pan-neural expression of TDP-43CTF:GFP#14  did not result reduced life span. 
  
Similarly, it was found that motor neuron specific TDP-43:GFP expression also 
resulted in loss of climbing ability in flies (Figure 14). It was observed highest 
expression of TDP-43WT#16 results in conspicuous loss of climbing starting already 
one day post eclosion as compared to the lower expression line TDP-43WT:GFP#10. 
Whereas TDP-43ΔNLS:GFP and TDP-43CTF:GFP remained less toxic than TDP-
43WT:GFP, TDP-43CTF:GFP exerted the least effect on climbing activity. 
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Figure 14: Motor neuron specific TDP-43 expression leads to loss of climbing 
ability. 
GFP-tagged TDP-43 variants TDP-43WT#10 (weak expression level) compared to TDP-
43WT#16 (intermediate expression level). Both show decline in climbing ability from day 1 to 
day 10, line 16 showing more drastic decline (dose dependency), however TDP-43CTF remains 
almost at similar level of climbing ability at day 1 v/s day 10. D42 driver only was used as 
control. Minor decline in climbing function was also seen in driver control, which might reflect 
effects of normal ageing. 
 
Key points learned from GFP tagged TDP-43 variants  
 
 TDP-43 variants localise as expected: TDP-43WT in nucleus, TDP-43ΔNLS and 
TDP-43CTF in cytoplasm 
 TDP-43WT exerts more toxicity then TDP-43CTF, toxicity ranges from TDP-43WT 
>TDP-43ΔNLS TDP-43CTF  
 TDP-43WT expression in eyes leads to REP  
 TDP-43WT expression in brain causes progressive age-dependent vacuolisation  
 TDP-43WT expression in muscles results in muscle degeneration and alteration 
in wing posture 
 TDP-43WT toxicity is dose dependent 
 TDP-43WT expression leads to a dose dependent life span reduction  
 Motoneuron specific expression of TDP-43WT results in motor function decline 
 
 
4.2  Site directed TDP-43 variants with comparable level of expression 
 Our initial analyses on the GFP-tagged transgenes suggested that expression of 
TDP-43WT caused a toxic gain-of-function in flies. This prompted us to ask whether the 
ALS linked mutations in TDP-43 might change toxicity of TDP-43. TDP-43 toxicity is 
dose-dependent was already shown. To be able to compare different variants of TDP-
43 with regard to toxicity, similar/identical expression levels had to be achieved. Thus 
new transgenes utilizing -C31 recombination in Drosophila [88, 93] were generated. 
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This method uses the -C31 integrase to achieve site-specific integration of P-
elements into the genome. This limits chromosomal variegation effects and - apart 
from specific knock-in strategies - represents the most advanced method to facilitate 
comparable expression levels of different transgenic constructs in vivo. Moreover, we 
were aware that any tag sequence might interfere with TDP-43 function. Therefore, all 
newly generated transgenes were devoid of any tag. 
 We generated transgenes for a series of TDP-43 variants using the -C31 site-
specific integration (Figure 16A). In addition to TDP-43WT, we generated synthetic 
mutants (SM) of TDP-43 (ΔNLS, CTF, FFLL) and transgenes expressing ALS/FTLD-
linked TDP-43 missense mutations (MS) in TDP-43 (A315T, A382T, G348C, G287S, 
N390D). Expression of trangenics constructs was controlled by UAS/Gal4 system, 
allowing targeted expression of TDP-43 in spatio-temporal manner.  
 In addition to the previously described TDP-43WT, TDP-43ΔNLS, TDP-43CTF 
another synthetic mutant TD-43FFLL was introduced. TDP-43 is known to effectively 
bind RNA [94]. To investigate whether this intrinsic function of TDP-43 might be crucial 
for TDP-43-mediated neurotoxic action, two missense mutations (F147L/F149L) were 
introduced into the first RNA recognition motif (RRM1). These mutations are known to 
abolish inherent TDP-43 RNA-binding function. In contrast to TDP-43WT, TDP-43FFLL 
displayed a complete inability to bind to UG12 RNA oligomers in pull-down assays [41].  
4.2.1 Subcellular localisation of untagged TDP-43 variants in Drosophila  
 In a first step, it was analysed whether the introduced ALS-linked or synthetic 
mutations alter the localisation of TDP-43. As for the GFP-tagged TDP-43 variants, 
larval salivary glands were used to assay the subcellular localisation of the new 
untagged TDP-43 variants in vivo. Except for TDP-43∆NLS, all transgenes localised to 
the nucleus. As expected TDP-43∆NLS showed cytoplasmic localisation. This suggested 
that the GFP-tag had no impact on subcellular localisation in previous analysis of TDP-
43WT and TDP-43∆NLS.  
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Figure 15: Localisation of TDP-43 in non-neuronal cells of Drosophila.  
Epifluorescence pictures of larval salivary glands cells expressing indicated TDP-43 variants. 
Glands were stained for TDP-43 (green) and f-Actin (red) using phalloidine (upper panel). 
Nuclear localisation of TDP-43WT and TDP-43MS (A, C-H) is visualised by colocalisation with 
DAPI (blue) stained nuclei (middle panel) and illustrated by plotted fluorescence distribution 
(lower panel). Line indicates distance used for fluorescence measure. Of all assayed TDP-43 
variants only TDP-43∆NLS displayed robust cytoplasmic localisation (B) [41]  
 
 Then various Gal4-drivers were used to test these TDP-43 transgenes for their impact 
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on fly viability. Using a strong ubiquitous driver (actin5C-Gal4), it was found that all 
variants caused  lethality except for the transgenic lines expressing TDP-43FFLL and 
TDP-43CTF. However, pan-neural induction of expression for all different transgenic 
lines resulted in viable offspring with no apparent phenotype (Table 9). 
Table 9: Viability assay of similar expression TDP-43 variants using pan-neural 
and ubiquitous driver.  
TDP-43 transgenes Gal4-driver lines used for assay 
Site-directed insertions elav-Gal4 actin5C-Gal4 
TDP-43 WT viable lethal 
TDP-43∆NLS viable  lethal 
TDP-43 FFLL viable  viable  
TDP-43 G287S viable  lethal 
TDP-43 A315T viable  lethal 
TDP-43 G348C viable  lethal 
TDP-43 A382T viable  lethal 
TDP-43 N390D viable  lethal 
TDP-43 CTF viable  viable  
 
 Subsequently, the expression of TDP-43 transgenes was verified on protein 
level. The pan-neural driver was used to express TDP-43 variants and total head 
lysates were subjected to Western blot analysis. 
Although it cannot be entirely ruled out that the introduced mutations in TDP-43 alter 
protein turnover/stability to some extent, no obvious differences in protein abundance 
of the different TDP-43 variants by Western blot analysis (Figure 16) was detected. In 
this Western blot analysis, TDP-43CTF was not detected. The TDP-43 antibody used 
was generated against a peptide that is partially missing in TDP-43CTF. This might 
explain why we achieved no/weak recognition of TDP-43CTF compared to full-length 
proteins in Western blot analysis. In addition to WB, we did qRT-PCR to assess 
relative TDP-43 expression. As expected, we found that the overall expression level of 
TDP-43MS variants were similar. TDP-43A315T and TDP-43N390D expression levels were 
found to be slightly, but significant elevated compared to that of TDP-43WT. In addition, 
we found that TDP-43CTF mRNA levels were roughly 3 fold higher compared to TDP-
43WT.   
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Figure 16: Analysis of untagged TDP-43 variants.  
(A) Schematic overview of the TDP-43 protein. Positions and nature of amino acid 
substitutions and size of C-terminal fragment (CTF) analysed are indicated. Synthetic 
mutations (SM) were introduced to interfere with TDP-43 localisation or function. Point 
mutation in the nuclear localisation signal (∆NLS) were introduced to target TDP-43 to the 
cytoplasm and mutations F147L/F149L (FFLL) in the first RNA recognition motive (RRM1) 
were introduced to impair TDP-43 inherent RNA-binding capacity. (B) Equalised expression of 
-C31-inserted TDP-43 variants in adult Drosophilae. TDP-43 expression was visualized using 
anti-human TDP-43 antibody. Syntaxin served as loading control. (C) mRNA abundance of 
TDP-43 variants normalized to actin5C and TBPH mRNA levels. Significant differences are 
indicated *p<0.05; ***p<0.001. Head lysates of flies with pan-neural expression of TDP-43 
were used for Western blot and qPCR analysis. Driver only (elav-Gal4) flies without TDP-43 
expressions were used as negative control [41] 
 
Our previous analysis of the GFP-tagged variants showed TDP-43 toxicity to be dose 
dependent. It was found that pan-neural expression of the different untagged TDP-43 
variants did not result in lethality. Thus it was interesting to see how our untagged 
variants behaved when co-expressed with TDP-43WT (localising in nucleus, 
physiological state) and TDP-43ΔNLS (cytoplasmically localising as seen in 
pathophysiological state). In order to achieve this, fly stocks with stable pan-neural 
expression of TDP-43WT or TDP-43∆NLS were generated. The results are summarised in 
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Table 10. In brief, co-expressing of the other TDP-43 variants almost exclusively 
caused lethality. The only exceptions were TDP-43CTF and TDP-43FFLL. Here, co-
expression of the two TDP-43 variants in elav>TDP-43WT or elav>TDP-43ΔNLS did not 
cause lethality. Another exception was observed by co-expression of TDP-43N390D .In 
elav>TDP-43WT this caused lethality, whereas co-expression of TDP-43N390D variant in 
elav>TDP-43ΔNLS background resulted in viable offspring.  
 
Table 10: Dose-dependent effect on viability for untagged TDP-43 variants  
TDP-43 variants were co-expressed with pan-neurally expressing TDP-43WT and TDP-
43∆NLS variant.  
 
Transgenes 
 
 
elav>TDP-43WT 
 
elav>TDP-43ΔNLS 
TDP-43WT Lethal Lethal 
TDP-43ΔNLS Semi lethal Semi lethal 
TDP-43CTF Viable Viable 
TDP-43FFLL Viable Viable 
TDP43A315T Lethal Lethal 
TDP43A382T Lethal Lethal 
TDP43G348C Lethal Lethal 
TDP43G287S Lethal Lethal 
TDP43N390D Lethal Viable 
 
4.2.2 Pan-neural expression of TDP-43 reduces longevity in Drosophila. 
 Our previous results suggsted that - except for TDP-43CTF and TDP-43FFLL all 
other TDP-43 variants caused toxicity in flies. Thus, we analysed flies with pan-neural 
expression of the different TDP-43 variants in longevity analysis (Figure 17). It was 
found that expression of all variants shortened life-span compared to control animals. 
Comparison among TDP-43 expressing flies revealed that TDP-43WT expressing flies 
had the shortest, TDP-43CTF the longest life-span. Relative impacts on survival differed 
notably between the TDP-43MS expressing flies: TDP-43N390D displaying the lowest, 
TDP-43A315T the highest reduction in median survival. Notably, TDP-43FFLL displayed a 
comparatively mild reduced longevity compared to TDP-43WT. A detailed statistical 
cross-correlation analysis showed significant differences (P value <0.0001) between 
the impacts of both, TDP-43WT and TDP-43CTF to all TDP-43 variants on longevity. In 
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contrast, longevity curves of flies expressing other TDP-43 variants displayed less 
significant (P value <0.05) or no significant differences to at least one other curve in the 
cross-correlation. 
 
Figure 17: Pan-neural expression of TDP-43 reduces longevity.  
(A) Flies with pan-neural (elav-Gal4) expression of indicated TDP-43 variants were assayed 
for longevity (genotypes elav-Gal4/Y;UAS-TDP-43/+). Survival curves of flies expressing 
indicated TDP-43 variants are displayed. (B) Median survival of respective survivial curves. (C) 
Cross-comparison of survival curves with regard to statistical significance after Bonferroni 
correction *p<0.05; **p<0.01; ***p<0.001; ns not significant. 
 
4.2.3 Motor neuron specific expression of TDP-43 impaired locomotion 
TDP-43 or cleavage products thereof were identified as the major component of 
inclusions found in ALS. As ALS is a motor neuron disease, it was tested whether 
there was toxicity upon motor neuron specific expression of TDP-43 and its variants in 
flies. Suggesting that Drosophila is a useful model organism, it should recapitulate this 
principle aspect of motor neuron related pathology of TDP-43 proteinopathy. Pan-
neural expression of TDP-43 eventually caused lethality, which was preceded by 
progressive impairment of locomotor activity and clapped/dropped wing phenotype. 
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The motor neuron specific driver D42-Gal4 to target TDP-43 expression to motor 
neurons (D42-Gal4>TDP-43) was used . All D42-Gal4>TDP-43 combinations were 
viable and displayed no obvious phenotype after hatching. Accordingly, these flies 
were used for the quantitative assessment of motor performance in climbing assays 
(Figure 18). Based on our findings in the longevity analysis, TDP-43WT, TDP-43A315T, 
TDP-43FFLL and TDP-43CTF were selected for this detailed analysis. 
 
Figure 18: Age-dependent locomotion defects after TDP-43 expression in motor 
neurons.  
(A) D42-Gal4 drives expression of TDP-43:GFP specifically in motor neurons as seen in whole 
mount thoracic ganglion of transgenic flies. (B) Flies expressing indicated TDP-43 variants 
specifically in motor neurons were assayed for negative geotaxis at one, ten and 20 days post 
eclosion. (C) Detailed summary of statistical analysis (2-way ANOVA followed by Bonferroni 
post-hoc tests) of age-dependent locomotion effects. Full genotypes of flies analysed 
w/Y;UAS::TDP-43/+;D42-Gal4/+ and w/Y;;D42-Gal4 served as control. 
*p<0.05;**p<0.01;***p<0.001; ns not significant [41]. 
 
In our analysis, D42-Gal4>TDP-43CTF and D42-Gal4>TDP-43FFLL flies displayed only a 
mild reduction in motor performance over time. In contrast, expression of TDP-43WT 
and TDP-43A315T led to progressive loss of motor performance, with TDP-43WT showing 
the highest reduction. These data is in line with the situation observed in longevity. At 
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day one of the analysis, about 80 - 90% of the tested flies managed the climbing task. 
The slight reduction in climbing ability of control flies (D42-Gal4 driver only) compared 
to TDP-43 expressing flies at day one of the analysis was unexpected. However, 
climbing ability of control flies remained stable at day 10 and showed only a slight 
reduction on day 20. In contrast, expression of TDP-43WT and TDP-43A315T led to 
significant progressive loss of motor performance at day 10 and 20. Although alive, 20 
days old D42-Gal4>TDP-43WT flies appeared severely paralytic, showing no apparent 
coordinated movement and failed to climb. Similar to control, flies TDP-43CTF and TDP-
43FFLL expressing flies showed a slight reduction in locomotion over time, which most 
likely refelects normal ageing rather than deterimental effects of TDP-43 as seen in 
TDP-43WT and TDP-43A315T expressing flies.  
4.2.4 TDP-43 expression leads to loss of neuromuscular function 
 Since it was observed neuronal loss as well as muscle loss, it was asked 
whether  neuronal decline is preceeded by dysfunction of the neuron. To address this 
question, adult flies were assayed for motoneuron function by recording of the dorsal 
longitudinal muscle (DLM). The DLM motoneurons are connected via the giant fiber 
system to the central brain. As the muscle is not activated by any other central brain-
connected neuron, recordings via the giant fiber can be considered as a one-to-one 
fashion. Brain stimulation of the giant fiber and subsequent recordings of the muscle 
response, thus resembling motoneuron function were performed . To assay the impact 
of TDP-43, D42-Gal4>TDP-43WT flies and compared these to driver only controls (D42-
Gal4) were used. Electrophysiological recordings on D42-Gal4>TDP-43WT flies 
revealed an abolished response of the neuromuscular junction (NMJ) in aged flies, 
while recordings of young flies were indistinguishable from controls. This implies that a 
disconnected or dysfunctional NMJ is responsible for reported locomotion deficits upon 
TDP-43WT expression. This experiment was performed by Tanja A Godenschwege at 
Florida atlantic University in collaboration with A. Voigt, fly lab Aachen. 
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Figure 19: Neuromuscular dysfunction in TDP-43 expressing flies. 
Electrophysiological recordings were performed to address response latency and the ability to 
follow stimuli one-to-one at high frequencies. Flies with motoneuron specific expression of 
TDP-43 displayed an abolished response of the NMJ over time, indicating a disconnection 
from motoneuron (Figure courtesy Aaron Voigt). 
 
4.2.5 Adult- onset model of TDP-43 proteinopathy. 
 To further confirm that observed reduction in longevity upon pan-neural TDP-
43WT expression was not due to a developmental phenotype. The adult-onset 
expression system, utilising a temperature sensitive Gal80[ts] antagonist of Gal4 was 
used. As expected, we were not able to detect TDP-43 in head lysates of flies raised 
under restrictive conditions. TDP-43 expression was observed in Western blot analysis 
already one hour after shifting flies to permissive conditions. Maintaining fies under 
permissive condition, TDP-43 expression was maintained as well. To prove this for 
other (untagged) TDP-43 variants, we used a selection of flies expressing tagged and 
untagged TDP-43 to analyse longevity (see Figure 13, Figure 17). Comparative 
analysis revealed dose-dependent toxicity also under these condition (TDP-43WT:GFP 
vs untagged TDP-43WT). Moreover, the differences in toxicity observed for the 
untagged TDP-43 variants with similar/identical expression levels was as expected. 
Also in the adult-onset expression system, TDP-43WT caused a strong reduction in 
longevity, as compared to other tested TDP-43 variants. These data are in line with the 
previous observation on longevity (see 43) and locomotion (see 4.2.3). Moreover, we 
showed that the TDP-43-induced reduction in longevity is not dependent on 
developmental alterations of the nervous system.  
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Figure 20: Adult-onset model of TDP-43 proteinopathy. 
(A) Verification of pan-neural adult-onset expression in Western blot analysis. Flies were 
raised at restrictive conditions (rc, 18°C), and TDP-43 expression was induced 2 days post 
eclosion by temperature shift (29°C). Head lysates taken at indicated time points were 
analysed for TDP-43 expression. No TDP-43WT:GFP expression could be detected under rc, 
but was induced at 29°C. Increasing TDP-43 protein levels were detected over time. (B) Flies 
with adult-onset pan-neural expression of indicated TDP-43 variants were assayed for 
longevity. Note that TDP-43WT:GFP#14 lethal in embryonic-onset expression paradigm, 
survived to adulthood in adulthood in adult-onset expression, but displayed a very short 
longevity after induction of expression. For untagged and site-directed TDP-43 transgenes, the 
order of toxicity is comparable to the embryonic onset paradigm. Groups of 10-20 male flies (0-
48 hours post hatching) per vial were shifted to 29°C and dead flies were counted daily. Fresh 
food vials were provided every second day. At least 60 flies were analysed per genotype.  
 
 
 
 
Key points learned from similar expression strength TDP-43 transgenes 
 TDP-43 toxicity ranges from TDP-43WT > TDP-43ΔNLS > TDP-43MS* >TDP-43FFLL > TDP-
43CTF 
 RNA binding activity of TDP-43 is required to exert toxicity 
 TDP-43 toxicity is not developmental phenotype 
 TDP-43-mediated toxicity appears to be independent from mutation, mislocalisation, or 
truncation 
 
*  MS- Missense mutations 
CHAPTER 4 – RESULTS    49 
4.2.6 RNA-binding activity is required for TDP-43-mediated motor neuron loss in 
chick 
In an a separate and independent investigation, a collaborating group of Till Marquardt, 
ENI Goettingen reproduced mirroring results in a vertebrate model system. The chick 
facilitates ready experimental access to mature vertebrate motor neurons through in 
ovo  transfection. Unilateral expression of TDP-43WT in postmitotic motor neurons for 
six days triggered loss of roughly 30% spinal motor neurons relative to the 
untransfected control hemicord. Expression of TDP-43NLS and TDP-43A315T also 
resulted in motor neuron loss but it was signifciantly milder than observed for TDP-
43WT. Loss of motor neurons was further preceded by transient increase in Caspase-
3+ positive motor neuron numbers, suggesting that motor neuron loss occurred at 
least in part via caspace-dependent apoptotic elimination. Expression of TDP-43CTF or 
RNA-binding deficient TDP-43FFLL did not trigger motor neuron loss compared to 
control vector transfection. These findings substantiated our fly data.  Also in chick the 
RNA-binding activity is required for TDP-43 mediated toxicity. In addition, it was also 
revealed that protein truncation/mislocalisation may have comparatively little impact on 
TDP-43-mediated neurotoxicity, since TDP-43CTF and TDP-43FFLL displayed 
predominantly cytoplasmic or nuclear localisation, respectively. To summarise, TDP-
43-mediated motor neuron loss in chick mirrors relative impacts of TDP-43 
mutation/mislocalisation in Drosophila.  
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Figure 21: RNA-binding activity is required for TDP-43-mediated motor neuron loss in 
chick. (A) Stable unilateral expression of human TDP-43 variants in chick (Gallus gallus) 
spinal cord. Schematic diagram of expression system mediating motor neuron-restricted 
expression upon unilateral transfection (B) Unilateral expression of human TDP-43FFLL (red) in 
embryonic day 9 (E9) chick spinal cord (nuclei labelled with DAPI: blue): transversal section at 
lumbar levels.”-” and “+” respectively indicate control and transfected hemicords. Isl1/2 labels 
motor neuron nuclei (green) (C) Quantification of motor neuron loss upon TDP-43 variants 
expression over all obtained sections (in ”-” versus ”+” hemicord). Differences relative to 
control (t-student’s test indicated) (D) Quantification of Caspase-3 activation in motor neurons 
of transfected hemichords versus vector control. Significant differences are indicated (t-student 
test). p<0.05,**p<0.01;***p<0.001; ns not significant. (Figure reproduced from [41] 
4.3 Recapitulation of key biochemical hallmarks of TDP-43 proteinopathy 
 TDP-43 inclusions found in ALS patients are characterised by abnormal 
phosphorylation, decreased solubility and ubiquitination. It was attempted to 
characterise whether these biochemical features of TDP-43 are conserved in 
Drosophila. Head lysates derived from flies with pan-neural expression of TDP-43 
were subjected to sequential extraction protocols, separating RIPA soluble and urea 
soluble TDP-43. Subsequent analysis of both fractions for TDP-43 abundance 
revealed increasing amounts of insoluble TDP-43 over time (Figure 22). Comparing 
TDP-43 abundance in Western blot analysis of young (two days) and old (20 days) 
CHAPTER 4 – RESULTS    51 
elav-Gal4>TDP-43WT flies showed transition from soluble to insoluble TDP-43 (Figure 
22A). While in young flies TDP-43 was found predominantly in the soluble fraction, it 
almost exclusively shifted to the urea fraction in aged flies. Interestingly, 
phosphorylated TDP-43 was almost exclusively detected in the urea fraction, whereas 
ubiquitinated TDP-43 was mainly present in the soluble fraction (Figure 22B). High 
molecular aggregates are difficult to detect in Western blot analysis. However, the so-
called filter retardation assay (for details see Material and Methods) provides an easy 
and fast detection of high molecular weight aggregates by simple size exclusion. Using 
this method, aggregated TDP-43 can be monitored. As expected, TDP-43CTF seems to 
be more aggregation prone as compared to TDP-43WT (Figure 22C). 
 
 
Figure 22: Disease associated modification of TDP-43. 
(A) Aggregation, cleavage and phosphorylation of whole brain lysates from TDP-43WT 
expressing aged flies revealed decreased solubility and strong abnormal phosphorylation 
signal from urea fraction (Anti Phospho TDP-43 ab- Gift from M.Neumann) (B) Adult-onset 
aged TDP-43WTGFP#14 flies also showed decreased solubility, phosphorylation and 
ubiquitination, Anti Ubiquitin (Dako, 1:500). (C) Filter retardation assay detected aggregates in 
urea fraction from TDP-43 (20 days) aged flies. 
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In summary, the presented biochemical analysis implies that TDP-43 in flies 
recapitulates  key features observed in TDP-43 proteinopathies.  
4.4 Genetic interaction between exogenous TDP-43 and endogenous 
TBPH in flies 
Cells preserve their vital properties and functions in part by the maintenance of correct 
protein homeostasis [50]. In cultured human cells, TDP-43 expression is reported to be 
tightly autoregulated [95]. TDP-43 has been shown to modulate its own protein level 
through a negative feedback loop by binding to its own RNA in the 3’UTR region [95]. 
This binding of TDP-43 to its own mRNA results in the degradation of the transcript.  It 
has been suggested that neurons should contain a relatively narrow range of TDP-43 
expression and that disruption of TDP-43 autoregulatory mechanisms might instigate 
the neurodegenerative process [95, 96]. In line with this hypothesis is the finding that 
C. elegans TDP-1 (worm homologue of TDP-43) regulates protein homeostasis [97]. 
The Drosophila TDP-43 homologue is called TBPH (coded by TBPH/CG10327). 
Others and we found that like TDP-43, TBPH primarily localizes in nucleus [54] (Figure 
23A). Western blot analysis showed higher TBPH abundance in head tissue compared 
to thorax [54]. Giving the autoregulatory mechanisms of TDP-43 in human cells, we 
wanted to test whether exogenous TDP-43 expression has an impact on endogenous 
TBPH. To address this question, comparative Western blot analysis of flies with and 
without exogenous TDP-43 expression (Figure 23B) was performed. Lysates derived 
from these flies were analysed for TBPH abundance. Neither in lysates of head nor in 
lysates of thoraxes, difference in TBPH levels (Figure 23C) was detected. In addition, 
transcript abundance of both TDP-43 and TBPH by qRT-PCR was analysed. The 
relative abundance of TBPH transcripts was not significantly changed between 
controls (OregonR and elav-Gal4) and TDP-43WT expressing flies. Thus, TDP-43 
expression does not seem to have detectable impact on TBPH transcript levels in flies. 
Finally, we addressed the relative amount of endogenous TBPH and exogenous TDP-
43 transcripts as overexpression of proteins in unphysiological high amounts might 
cause cytotoxicity. TDP-43 and TBPH mRNA-levels in head lysates derived from elav-
Gal4>TDP-43WT flies was determined. Interestingly, endogenous TBPH was 
consistently more abundant (approx. 5-fold) compared to exogenous TDP-43. This 
implies that exogenous TDP-43 levels are low. Thus, toxicity observed after expression 
of the untagged TDP-43 variants is most likely not caused by protein abundance within 
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an unphysiological range.  
 
Figure 23:  Analysis of endogenous TBPH (fly homologue of TDP-43). 
(A) Epifluorescent pictures of larval salivary glands. Glands were stained for TBPH (left) and 
DNA (DAPI, middle). As seen in the overlay (right), TBPH predominantly localizes to the 
nucleus. (B) Western blot analysis showed that TBPH is more abundant in head as compared 
to thorax. Tubulin was used as loading control. (C) Depicted is the relative abundance of 
endogenous TBPH transcripts normalised to Actin5C. No differences in TBPH abundance was 
detected comparing wild type strain Oregon R (OreR), the pan-neural driver line elav-Gal4 and 
in elav-Gal4>TDP-43WT flies [41] 
 
 Although any autoregulatory functions of TDP-43 on TBPH was not detected, 
the possiblity that reduced TBPH might interfere with TDP-43-induced toxicity was 
analysed. To investigate this hypothetical interaction the REP induced by eye specific 
expression of TDP-43WT: GFP was used. Such REPs are usually sensitive towards 
genetic modifiers. Depending on the genetic interaction, the severity of the REP is 
either enhanced or suppressed (Figure 24A). GT flies were crossed to TBPH[null] 
mutant flies [98]. In the F1 generation, GT carrying one TBPH[null] allele was selected. 
A mild effect of the TBPH[null] allele on the TDP-43WT-induced eye phenotype (Figure 
24A; compare TBPH-/+ with TBPH+/+) was observed. However, this effect was not as 
conspicuous as other modifiers identified in this study. In order to quantify these subtle 
changes on the TDP-43-induced REP, a 10 point scoring system (for details, see 
Material and Methods 3.2.4) was developed. Using this system, a significant reduction 
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of the REP by reducing TBPH levels (Figure 24B) was detected. However, such mild 
effects were also observed in other flies without TBPH reduction. For example, 
balancer flies resulting from the cross used for analysis displayed a similar rescue 
effect as the TBPH[null] allele. Given the subtle differences in phenotypic outcome as 
compared to the strong effects observed for other modifiers, this experimental outcome 
was not conclusive. 
 
 
 
Figure 24: Partial rescue of TDP-43WT induced REP by reducing TBPH levels. 
(A) Representative eye pictures of flies showing genetic interactions. Crosses were performed 
using virgins w;GMR-Gal4,UAS:TDP43WT:GFP#14/CyO to: w/Y;;Def/TM3,Sb  
(enhancer/suppressor) and  w/Y;TBPH[null]/CyO (TBPH-/+) or w/Y;Sco/CyO (TBPH+/+).  
Genotypes of the F1 generation analyzed were: (i,iv) w;GMR-Gal4,UAS:TDP-
43WT:GFP#14/+;Def/+(suppressor/enhancer)(ii)w;GMRGal4,UAS:TDP43WT:GFP#14/TBPH[null
]; (TBPH-/+), 50% reduction in TBPH dose. (iii) w;GMR-Gal4,UAS:TDP-43WT:GFP#14/Sco; 
(TBPH+/+) (B) Eye score (see Materials and Methods 3.2.4) was significantly different - 
Unpaired t test (one tailed): ***p< 0.0001  
 
 The previous inconclusive finding prompted us to use more sophisticated 
analysis to address whether alteration in TBPH levels alters TDP-43-induced toxicity. 
Thus, it was analysed whether TDP-43 mediated life span reduction was rescued by 
concomitant expression of a shRNAi line against TBPH to silence protein expression 
henceforth called (TBPH-RNAi). qRT-PCR analysis showed that TBPH-RNAi 
effectively reduced endogenous TBPH mRNA levels (data not shown). Using TBPH-
RNAi, it was first tried to rescue the lethal phenotype of elav>TDP-43WT:GFP#14 flies. 
Concomitant pan-neural expression of TBPH-RNAi and TDP-43WT:GFP#14 did not 
rescue lethality. However, it was found that the TBPH-RNAi partially ameliorated the 
shortened life span induced by expression of the untagged TDP-43WT (data not 
shown).  
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Taken together, it was not convincingly proven that a reduction in endogenous TBPH 
levels could suppress detrimental effects induced by exogenous TDP-43 expression  
4.4.1 Inclusions formed by TDP-43CTF are reversible in flies. 
 Prior experiments performed by A.Voigt overexpressing different TDP-43 
variants in human embryonic kindney (HEK) cells revealed that cytoplasmic localised 
TDP-43CTF and TDP-43∆NLS form distinct accumulations (Figure 25A). Whereas TDP-
43WT localises to the nucleus, cytoplasmic TDP-43∆NLS tends to accumulate in multiple 
small foci distributed throughout the cell, most likely representing aggregates. In 
contrast, TDP-43CTF predominantly forms one large, perinuclear accumulation that co-
localises with Vimentin foci. Thus, these structures are most likely aggresomes.  
In flies, TDP-43CTF seems to accumulate as well. We were able to detect insoluble 
protein in filter retardation assay (see Figure 22). Although this assay can not 
discriminate aggregates and aggrosomes, it was assumed that TDP-43CTF 
accumulates in one or both of these structures. 
Protein accumulations are present in many neurodegenerative diseases. This common 
feature of the different diseases led to the assumption that aggregates/aggresomes 
might trigger toxicity. Our finding that TDP-43WT but not TDP-43CTF in flies exerts 
toxicity (assayed in longevity and climbing) is not in favour of this hypothesis.  
This prompted us to analyse whether the formation of TDP-43CTF containing 
accumulations is reversible. It has been already shown by Zhang et al. that CTF 
inclusions were reversible and cleared through UPS in a human neuroblastoma cell 
line [72]. Pan-neural expression of TDP-43CTFGFP#14 (highest CTF expression levels 
among all randomly insertions transgenes) in Drosophila was utilised in our adult onset 
expression system. To be able to monitor generation and potential removal of 
accumulated TDP-43CTF, flies were raised  at restrictive conditions and induced 
expression of TDP-43CTF in adult flies (0-2 days post eclosion). Flies were then kept 2 
days at permissive temperature to allow formation of insoluble accumulation. Then, 
flies were shifted back to restrictive conditions blocking further generation of TDP-
43CTF. Using this paradigm, we were able to show that previously formed insoluble 
TDP-43CTF disappeared over time (Figure 25B).  
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Figure 25: CTF inclusions formation is reversible. 
(A) HEK cells transiently transfected with indicated TDP-43:GFP variants were stained for 
Vimentin (red, left) or DNA with DAPI (blue) in the overlay (right). Bar graphs display the 
quantification of the subcellular distribution of the different TDP-43 variants in transfected cells. 
(Figure courtesy Aaron Voigt). (B) Western blot analysis of head lysates derived from flies with 
inducible pan-neural TDP-43CTF:GFP expression. Lysates were seperated in soluble and 
insoluble fractions prior to Western blot analysis. TDP-43CTF:GFP was detected using anti-GFP 
antibody. Detection of Synapsin served as loading control. Genotype of flies used for analysis: 
elav-Gal4/y;Gal80[ts]/TDP-43CTF:GFP. 
 
4.4.2 Cellular quality control system and removal of TDP-43 aggregates  
 Cell culture based studies showed that TDP-43 is processed and degraded by 
autophagy and ubiquitin proteasomal system (UPS) [99]. The UPS is suggested to be 
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the primary clearance mechanism for TDP-43 aggregates, as proteasome inhibition in 
cultured neurons resulted in TDP-43 cytolasmic mislocalisation and aggregation [100]. 
Moreover, it has been shown that CTF inclusions were reversible and cleared through 
UPS in a human neuroblastoma cell line [72]. A recent study indicates that TDP-43 
acts as a maintenance factor of the autophagy system [101]. Thus it was speculated 
that TDP-43 LOF contributes to disease [101]. Finally, there is some in vivo evidence 
of motoneuron specific disruption of the proteasome, but not autophagy replicates 
TDP-43 related  pathology in mice [102]. Although there is agreement on some 
aspects of TDP-43 aggregation, there are several open questions: 1. Do TDP-43 
aggregates confer toxicity? 2. Are aggregates reversible structures? If so, which 
cellular mechanism facilitates degradation of TDP-43 aggregates? 3. At which stage of 
aggregate formation is TDP-43 cleaved? 4. What are the roles of ubiqutinylation and 
phosphoraylation in aggregation? Using our fly model for TDP-43 proteinopathy, we 
tried to answere these questions. 
4.4.3 Ubiqutin- proteasome pathway is involved in the clearance of aggregates 
In a first attempt, the question whether inhibition of the proteasome enhances toxicity 
of TDP-43 was addressed. The well-known proteasomal inhibitor MG-132 is known to 
function in flies and has been successfully used to inhibit proteasome function 
previously [103]. This enabled us to address the effect of chemical inhibition of the 
proteasome on TDP-43-induced toxicity. Longevity analysis of elav-Gal4>TDP-
43WT:GFP#16 flies treated with the proteasomal inhbitor MG-132 revealed a reduction 
in life span and motor phenotypes as compared to controls (Figure 26A). Moreover, 
MG-132 treated flies showed elevated levels of insoluble TDP-43 in Western blot 
analysis (Figure 26B).  
The reduction in longevity observed in MG-132 treated elav-Gal4>TDP-43WT:GFP#16 
flies suggests that proteasomal inhibition might enhance toxicity of TDP-43. To further 
test this hypothesis, it was analysed whether silencing of proteasomal subunits by 
RNAi might enhance the TDP-43-dependent REP. Concomitant silencing of several 
proteasomal subunits in GMR>TDP-43WT:GFP#14 flies indeed  enhanced the TDP-43-
induced REP (Figure 26C) indicating loss of proteasomal functioning is enhancing 
TDP-43 induced toxicity.  
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Figure 26: Effect of MG-132 on flies expressing TDP-43. 
(A) Longevity analysis of flies with pan-neural expression of TDP-43:GFP (intermediate 
expression). Freshly eclosed male flies were transferred either on MG-132 supplemented food 
or control food. MG-132 fed flies have reduced life span as compared to DMSO control and 
water control DMSO v/s water p*<0.025, MG132 v/s DMSO p***<0.0001.  Survival curves and 
Logrank comparisons between curves were calculated using GraphPad Prism, Total number of 
flies in respective groups were n=94 (MG-132 treated group), n=66 (DMSO), n=36 (water 
control) (B) Western blot analysis, clearence of CTF-GFP aggregates in the presence of 
proteasomal inhibitor MG132. In flies on normal cornmeal agar food the aggregates seem to 
get cleared but in flies fed on MG132 containing food aggregates load seem to be more 
pronounced. (C) RNAi-induced gene silencing of proteasomal subunits enhanced TDP-43 
induced REP. Representative eye pictures of GMR>TDP-43WT#14 -GFP flies with concomitant 
RNAi-mediated silencing of indicated genes. CG3422/Prosα4; CG4569/Prosα4T2; 
CG3329/Prosβ2 and CG1519/Prosα7. (D) Proteasomal dysfunction in eye disc of TDP-43WT 
expressing flies (i) Temperature sensitive proteasomal subunit DTS7 mutant severley 
enhanced REP associated with expression of TDP-43WT (ii) CL1 mediated GFP fluorescent 
signal for sensing protesomal dysfunction was used to investigate proteasomal stress. Low 
fluorescent signal in GMR driver control eye imaginal disc reflecting an active UPS, however in 
TDP-43WT untagged flies, flourescent signal is conspicously higher indicating proteasomal 
stress in TDP-43 expressing eye discs. 
 
             CL1:GFP is an established fluorescent reporter of UPS function [81]. Once 
UAS-dependent expression of the CL1:GFP fusion protein is initiated, it is rapidly 
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degraded by the UPS. Accordingly, CL1:GFP steady levels reflect the functional status 
of the UPS. Eye imaginal discs expressing the CL1:GFP reporter emits a low 
flouroscent signal reflecting an active UPS (Figure 27D (ii)). CL1:GFP was co-
expressed in GMR>TDPWT(untagged) flies, the flourescent signal from UPS reporter 
was conspicously high indicating proteasomal impairment which might be associated 
with TDP-43 toxicity (Figure 27D (iii)). Further, the effect of a mutant proteasomal 
subunit was studied. DTS-7 is temperature sensitive dominant negative mutant of the  
proteasomal β2 subunit [81]. Eye targeted DTS7 expression causes eye restricted 
proteasome impairment. At 18°C proteasome function is intact and eye morphology is 
normal, however at 29°C proteasome impairment causes degeneration [81]. Co-
expression of DTS7 mutant with TDP-43WT at 29°C  resulted in eye necrosis, (Figure 
27D (i)). These data indicates the involvement of UPS in clearance of TDP-43.  
4.4.4 Role of autophagy in the clearance of aggregates  
Several recent studies imply an involvement of autophagy in TDP-43 toxicity and/or in 
the clearance of TDP-43 inclusions [104]. It was found that chemical inhibition of the 
UPS enhanced toxicity induced by TDP-43 expression. Thus, a similar approach was 
taken to address the role of authophagy in TDP-43 toxicity. Autophagy is regulated by 
mTOR signalling. The mTOR pathway is evolutionary conserved. It functions as main 
regulator of many crucial cellular processes, including autophagy, protein translation, 
mRNA transcription and cytoskeltal organisation [105]. 
Thus, interfering with this pathway might/will have different cellular outcome, with only 
one being the regulation of autophagy. A schematic overview of the TOR pathway is 
provided in (Figure 27). Two drugs were used to alter activity of the TOR pathway. One 
was Rapamycin, eponymous for the TOR (Target Of Rapamycin) pathway. Rapamycin 
inhibits mTOR signaliing, thereby activating autophagy. Its is already reported that 
Rapamycin increases life span in flies expressing other neurotoxic proteins or peptides 
[106]. We confirmed these findings and showed that administration of Rapamycin to 
flies expressing toxic polyglutamine stretches decreased toxicity (Figure 27B(i)). 
Testing the effect of Rapamycin on toxicity induced by TDP-43, a protective effect of 
Rapamycin on TDP-43 toxicity in longevity analysis (Figure 27B(ii)) was also observed. 
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Figure 27: Rapamycin rescues TDP-43 induced toxicity 
(A) Autophagy is negatively regulated by mTOR, which is downstream target of PI3K and 
AKT/PKB. Rapamycin functions as an mTOR inhibitor and triggers mTOR dependent 
autophagy induction [104]. (B)(i) Rapamycin increases life span of Poly Q (SCAtr-Q78) flies. 
Blue curve depicts Poly Q flies on instant food where black curve depicts Poly Q flies on 
rapamycin substituted food. Survival curves differ significantly; (p***<0.0001)(ii) Survival 
curves for Rapamycin fed TDP-43 flies. Black curve depicts TDP-43 flies on rapamycin 
subsituted food whereas Green curve represents TDP-43 flies on normal food. (p****<0.0001). 
Statistical analysis was done using GraphPad prism, Log rank test was applied.  
 
In addition to the regulation of autophagy, the TOR signaling pathway controls other 
processes, two of them tightly linked to protein translation. First, TOR phosphorylates 
and thereby causes the activation of S6K. Active S6K in turn enhances overall protein 
synthesis by stimulating the synthesis of ribosomal proteins.  
On the other hand, TOR regulates protein translation by phosphorylating 4E-BP. 
Unphosphorylated 4E-BP efficiently binds the eukaryotic initiation factor 4E (eIF-4E) 
and threby prevents elF-4E dependent translation. Upon phosphorylation of 4E-BP by 
TOR, 4E-BP loses this binding ability and free elF-4E initiates translation efficiently.  
 We were eager to test wheter impaired translational control might contribute to TDP-
43 toxicity in flies. In a first step, the role of S6K was addressed. As this kinase is a 
downstream effectors and activated upon phosphorylation by TOR, phosphomimetic, 
constitutively active variants (fly lines) of S6K [107] were used. Eye specific expression 
(GMR-Gal4) of these constitutively active S6K variants had no impact on eye 
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morphology. However, when crossed to GT flies, active S6K strongly enhanced the 
TDP-43-induced REP (Figure 28). Similar results were obtained when the effect of eIF-
4E overexpression was analysed. Whereas eye specific overexpression of eIF-4E had 
no impact on eye morphology, it strongly enhanced the REP in GT flies (Figure 28). 
Interestingly, the observed genetic interaction of S6K and eIF-4E with TDP-43 seemed 
to be specific. Eye-specific expression of Amyloid beta-42 (A42) also causes a REP 
sensitive to genetic interactions [206]. However, co-expression of S6K or eIF-4E in this 
background did not change the A42-induced REP.  
 GMR GMR>A42 GMR>TDP-43 
BL# 6910  
W[1118];P{W[+MC]=UAS-
S6K.M}2/CYO 
   
BL#6912 
W[1118]; P{W[+MC]=UAS-
S6K.TE}2 
   
BL#6913 
W[1118]; P{W[+MC]=UAS-
S6K.STDE}3 
   
BL#6914 
W[1118]; P{W[+MC]=UAS-
S6K.STDETE}2 
   
BL#8650 
W[*]; P{W[+MC]=UAS-EIF-
4E.R}2 
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BL#8710 
W[1118]; P{W[+MC]=UAS-
EIF-4E.A}26 
   
BL#8711 
W[1118]; P{W[+MC]=  
UAS-EIF-4E.S251A}8 
   
Figure 28: TDP-43 and mTOR signalling components crosstalk. 
Analysis of mTOR pathway revealed TDP-43 is involved in translational regulation. Pictures of 
adult eyes with GMR-Gal4 driven overexpression of S6K (wild type or its constitutive active 
variants S6K-TE, S6K-STDE and S6K-STDETE) and eIF-4E (variants) alone (left), or with 
concomitant expression of either A42 or TDP-43.  Note that eye morphology is not changed 
when S6K or eIF-4E are expressed alone. Moreover, co-expression of S6K or eIF-4E des not 
alter the very mild REP induced by A42 (middle). Just in combination with TDP-43, enhanced 
REP or even lethality is observed (right).  Eyes are oriented anterior - left and dorsal - up. 
 
                 This data suggests that the regulation of protein translation by TOR impacts 
TDP-43 toxicity. In addition, autophagy was specifically blocked. An established 
autophagy inhibitor is 3-Methyladenine (3-MA), blocking autophagosome formation via 
the inhibition of type III Phosphatidylinositol 3-kinases (PI-3K). However, PI-3Ks act 
also upstream of TOR and accordingly 3-MA might also (at least partially) inhibit 
downstream effectors of TOR.  
 
 
Figure 29: Effects of autophagy inhibition via PI3K in GMR>TDP-43 flies. 
 (i) Expression of a dominant negative variant of PI3K had no effect on eye morphology (GMR 
only), whereas it enhances REP of GT flies (compare (ii) and (iii)). Concominant expression of 
PI3K dominant negative variant with GT flies (iii). Eyes are oriented anterior - left and dorsal - 
up. 
 
To avoid this caveat, we decided to inhibit autophagy genetically. RNAi-mediated 
silencing of a series autophagy related genes (several of them known to be essential 
for autophagy) in GT had no or only mild impact on REP formation (Figure 30).    
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Gene 
name 
CG number 
  Human 
homologue* 
Molecular function/ 
process** 
       REP  
Atg1 CG10967 ULK2 
Protein Serine/Threonine 
kinase 
 
Atg 4 CG4428 ATG4A 
Cysteine-type 
endopeptidase activity 
 
Atg 6 CG5429 BECN1 Autophagic cell death 
 
Atg 7 CG5489 ATG7 
Catalytic activity, 
nucleotide binding 
 
Atg 8a CG32672 GABARAP 
Regulation of protein 
ubiquitination, 
macroautophagy 
 
Atg 8b CG12334 GABARAPL1 Macroautophagy 
 
Atg 9 CG3615 ATG9A 
Autophagic vacuole 
assembly 
 
Atg 18 CG7986 WIPI2 Macroautophagy 
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Figure 30: Effect of silencing autophagy related genes in TDP-43 induced REP. 
  
 *Human homologue as listed in Homologene database, or found by BLAST analysis. Official 
symbol as listed in the Gene database of NCBI, ** reference from Flybase, where molecular 
function is unknown Biological process (BP) is stated as listed in the Gene Ontology 
Annotation Database. Eyes are oriented anterior - left and dorsal - up. 
 
This data suggests autophagy might not be primarily involved in TDP-43 clearance, 
since strong enhancement of TDP-43 induced REP after silencing autophagy related 
genes in Drosophila were not observed. Further phenotypes, observed after 
coexpression of TDP-43 and mTOR signalling components suggests strong role of 
TDP-43 in protein translation related pathways. 
4.5 Genome-wide screen of modifiers of TDP-43 toxicity  
 In previous experiments of this study it has been show that the eye-specific 
(GMR-Gal4) expression of TDP-43WT resulted in a moderate rough eye phenotype 
(REP) in adult flies (see Figure 10)[42] [108]. Moreover, it was shown that the severity 
of the TDP-43-induced REP correlated with the loss of photoreceptors (Figure 10). 
Thus, changes in the REP indicate suppressed or enhanced photoreceptor/neuron 
loss. Such REPs are frequently used as readout in high throughput screens for 
neurodegenerative diseases [82, 84, 109, 110]. Modifier screens rely on genetic 
interactions. If a given gene product acts in a process/pathway modulating TDP-43-
induced toxicity, alterations in the abundance of this gene product should result in REP 
changes.  
The REP induced by eye-specific expression of TDP-43 is a suitable readout for a 
modifier screen and allows the identification of enhancers and suppressors of TDP-43 
induced toxicity.  
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Figure 31: Screening paradigm to identify modifiers of TDP-43 toxicity  
Pictures of fly eyes showing an enhanced (left) and suppressed (right) REP observed in GT 
flies (middle). Concomitant RNAi-mediated gene silencing in eye can modulate REP, as 
indicated. Eyes are oriented anterior- left and dorsal- up. 
 
In addition, various proteins have been identified as TDP-43 interactors. To functionally 
prove our screening paradigm, we tested whether silencing expression of the genes 
coding for these proteins has an impact on the TDP-43-induced REP (see Figure 32).  
It has been previously shown that loss of TDP-43 causes HDAC6 downregulation [98]. 
HDAC6 is necessary for protein aggregate formation and degradation. It was found 
that co-expressing HDAC6 suppressed the TDP-43 induced REP, indicating a possible 
crosstalk of TDP-43 and HDAC6. In addition, VCP/ter94, which is another, confirmed 
candidate implicated in TDP-43 related neuropathology was tested [111]. VCP is a 
ubiquitously expressed chaperone that extracts misfolded proteins from the ER and 
facilitates the degradation of proteins via the UPS and autophagy pathway. VCP co-
localises with TDP-43, Ataxin-3 or ubiquitinated inclusions in Alzheimer’s disease and 
Parkinson’s disease [112]. It was found that silencing of VCP enhanced the TDP-43 
induced REP in GT flies. However, this interaction does not seem to be specific to 
TDP-43-induced toxicity. Silencing VCP also enhanced REPs induced by expression 
of polyQ, Tau and Aβ42. Physiological TDP-43 shuttles between nucleus and 
cytoplasm [44],  thus two genes involved in nuclear transport Ntf-2r whose human 
homologue is NUTF2 nuclear transport factor 2 and CG13387 (XPO1, human 
homolgue: exportin 1) were randomly tested. Silencing the expression of both, Ntf-2r or 
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CG13387 enhanced the TDP-43-induced REP. This suggests that interference with 
endogenous nucelocytoplasmic shuttling of TDP-43 has detrimental effects.  
 
Figure 32: Testing GMR>TDP-43 (GT) flies with biased candidates. 
As a biased approach we tested already known TDP-43 linked genes as well as some genes 
implicated to function in TDP-43 toxicity. Shown here is concomitant expression of TDP-43WT 
and dHDAC6, which suppressed TDP-43-induced REP, whereas silencing TER94 (fly 
homologue of VCP), CG10174 (fly homologue of nuclear transport factor 2) and CG13387 (fly 
homologue of human exportin1) involved in nuclear transport enhanced TDP-43 induced REP. 
Eyes are oriented anterior - left and dorsal - up. 
 
The above-described results can be regarded as validation of the screening approach 
in general.  
4.5.1 Primary screen. 
The primary screen was conducted using flies from ‘Bloomington Deficiency kit’, which 
comprise of a collection of transgenic fly lines, each carrying a defined chromosomal 
deletion, so-called deficiencies. A collection of fly lines (“deficiency kit”), with over-
lapping     deficiencies    is        available     in          a public stock center 
(http://flystocks.bio.indiana.edu/Browse/df/dfkit-info.html). In sum, these overlapping 
deficiencies cover more than 95% of Drosophila autosomal euchromatin and allow for 
genome wide screening. 
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Figure 33: A flowchart of the conducted screen to identify modifiers of TDP-43 
induced toxicity. 
 
To identify modifiers of TDP-43 induced toxicity, GT flies were crossbred with flies 
carrying a given deficiency. In the resulting offspring (F1 generation), we selected for 
GT flies also carrying the genomic deletion. If available, these flies were analysed for 
enhancement/suppression of the TDP-43-dependent REP. Deficiencies lines identified 
to cause a synthetic haploinsufficiency or an obvious enhancement/suppression of the 
REP were crossed thrice for confirmation purpose. To test for specificity of the 
observed interaction, these deficiencies were tested for genetic interaction with A42-
induced REP. Deficiencies showing similar effects on GMR>Aβ42 induced REP were 
considered to be not specific for TDP-43 toxicity and thus excluded from analysis. 
In summary, all 224 autosomal deficiencies were screened and 26 deficiencies were 
identified to induce a specific modification of the TDP-43 dependent REP. The majority 
(22 deficiencies) of genetic interactions caused an enhancement, while only 4 
deficiencies suppressed the TDP-43 dependent REP. A brief overview of identified 
deficiencies is given in Table 11. 
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Table 11: An overview of identified genomic deficiencies modulating TDP-43 
induced REP. 
Bloomington No Deletion points Mapped small region Effect on TDP-43 
induced REP 
BL#8672 Df(2L) BSC106 
21B7-21C2 
- Suppressor 
BL# 3084 Df(2L)ast2 
21D1-22B3 
21F1-22A1 Enhancer 
BL#490 Df(2L)E110 
25F3-26D11 
26B4-26B11 Suppressor 
BL# 2892 Df(2l)N22-14 
29C1-30C9 
29D5-F8 
 
Enhancer 
BL#3366 Df(2L)J2 
31B-32A 
31B1-31D9 Lethal 
BL#7142 Df(2L)BSC32 
32A1-32D1 
32D4-F2 Enhancer 
BL#7143 
BL#5869 
 
Df(2L)BSC36 
32D1-32E1 
Df(2L)FCK-20 
32D1-32F3 
- Suppressor 
 
BL#7421  
Df(2L)ED784 
34A4-34B6 
- Enhancer 
BL#26865 Df(2L)BSC768 
34A9-34B8 
- Enhancer 
BL#3588 Df(2L)TE35BC-24 
35B4-35F7 
35E1-35F1 Enhancer 
BL#1491 Df(2L)r10 
35D1-36A7 
- Enhancer 
 BL#28663 Df(2L)BSC278 
35E1-35F1 
- Enhancer  
             BL#420 Df(2L)TW137 
36C2-37C1 
36C8-36E3, 
37A2-37B6 
Enhancer 
BL#9410 Df(2R)BSC132 
45F6-46B4 
46B2-46C7 Semi-lethal 
BL#442 Df(2R)CX1 
49C1-50D2 
 
50B6-50C18, 
50C6-50D2 
Lethal 
BL#3518 Df(2R)Jp1 
51D3-52F9 
51F13-52F9 Lethal 
BL#5680 Df(2R)robl-c 
54B17-54C4 
54B16-54C1 Enhancer 
BL#6647 Df(2R)BSC22 
56D7-56F12 
- Enhancer 
BL#5246 Df(2R)Egfr5 
57D2-58D1 
57E6-58A1 Lethal 
BL#3096 Df(3L)ZN47 
64C-65C 
- Enhancer  
BL#4500 Df(3L)Scf-R6 
66E1-66F6 
- Enhancer 
BL#6456 Df(3L)BSC10 
69D4-69F7 
69D4-69E8 Enhancer 
BL#7623 Df(3R)Exel6144 
83A6-83B6 
-  Enhancer  
BL#8103 Df(3R)ED5177 
83B4-83B6 
- Enhancer  
BL#823 Df(3R) D605 
97E3-98A5 
- Suppressor 
 
BL-Bloomington identifier number 
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4.5.2 Secondary screen 
On average, each of the screened deficiencies deletes /lacks about 65 protein-coding 
genes. In order to identify the single gene(s) responsible for the genetic interaction, 
fine mapping of candidate cytological regions and single gene analysis was performed. 
In a first step, small overlapping deficiencies were used to narrow down the genomic 
region/number of genes potentially responsible for the observed REP modification 
(Figure 10). Having trimmed down the deleted segment to the smallest region possible, 
analysis was switched to single gene. In single gene analysis, it was asked whether 
RNAi-mediated silencing of a gene has an impact on the REP in GT flies. We were 
interested to identify gene products that modify toxicity of human TDP-43 to gain 
insights in the pathology of TDP-43 linked diseases like ALS and FTLD-U. Accordingly, 
our single gene analysis was restricted to those genes, of which we were able to 
indentify human orthologes.  
Candidate genes were classified by their Gene Ontology (GO) terms including 
molecular function and biological process as found at Flybase (flybase.org). Human 
orthologues were identified using Homologene or by blasting protein sequences. 
During classification of candidates the most congruent GO terms (function and process 
of Drosophila and human gene products) were taken into account. Thereby, some 
candidate genes were redundant for two or more groups. However, candidates were 
only categorised to the group that appeared more likely to reflect its involvement in 
TDP-43-mediated toxicity. After a detailed look at GO terms, all the candidates can be 
broadly classified in following divisions: DNA/RNA related, protein/signaling related, 
and cellular energetics and cell metabolism. A detailed list is presented in Table 12 
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Table 12: List of candidates modulating TDP-43 induced REP 
Drosophila 
gene silenced 
Human 
Homolog 
 
GO Process/ function 
Drosophila 
 
GO 
Process/function 
 (Human) 
 
REP 
Modification 
                                                        DNA/RNA related 
CG4881 SALL1 Transcription regulation  
DNA binding, protein 
binding, 
chromatin binding 
E 
CG2931 RBM42 
mRNA splicing via 
spilceosome 
RNA binding, 
nucleotide binding  
E 
ebi TBL1X Chromatin binding 
Transcription 
regulation 
E 
vvl POU3F3 DNA binding 
Transcription 
regulation 
E 
CG4957 TACO1 mRNA splicing 
Translation 
regulation 
E 
RfC38 RFC3 
DNA replication, 
neurogenesis 
Replication 
E 
Snm1 - DNA repair DNA repair E 
CG9154 N6AMT2 
Methyltransferase 
activity, nucleic acid 
binding. 
Methyltransferase 
activity, nucleic acid 
binding. 
E 
pix ABCE1 
Ribosomal binding, 
translation  
ATP binding, RNA 
catabolic process 
E 
mago MAGOH mRNA splicing 
RNA metabolic 
process, splicing 
E 
Rga CNOT2 Transcription regulation RNA metabolism L 
noi SF3A3 Splicing       RNA splicing E 
CG5343 C16orf80 
mRNA splicing, 
transcription factor 
mRNA splicing, 
transcription factor 
S 
CG30291 CDK5RAP3 
Regulation of cyclin-
dependent protein 
serine/threonine kinase 
activity 
Positive regulation 
of transcription/ 
neuron 
differentiation 
regulation 
S 
qkr54B KHDRBS3 RNA/ mRNA binding 
DNA-dependent 
regulation of 
transcription 
S 
RnrL RRM1 
DNA replication/ 
oxidation –reduction 
process 
Replication 
S 
Utx KDM6A 
Histone demethylase 
activity. 
Histone H3-K4 
methylation 
S 
Sap130 SAP130 
Mitotic spindle 
organization 
HistoneH3 
acetylation, 
transcription 
regulation 
S 
Cand1 CAND1 
Negative regulation of 
protein neddylation/ 
transcription factor 
binding 
Transcription 
regulation/protein 
ubiquitination 
S 
Ubp64E USP47 
Proteolysis, regulation of 
chromatin silencing, 
ubiqutin-dependent 
protein catabolic process 
Transcription 
regulation/ 
ubiquitin dependent 
protein catabolic 
process 
         S  
CG4887 RBM5 mRNA splicing via RNA splicing, S 
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spliceosome regulation apoptosis, 
cell proliferation. 
CG10576 PA2G4 Aminopeptidase activity 
Translation/transcrip
tion regulation 
S 
al - Transcription regulation - S 
CG10948 ENOX1 - 
Electron transport 
chain, nuclein acid 
binding 
E 
CG17098 - 
Nucleic acid binding/zinc 
ion binding 
- 
S 
                                       Protein related /Signalling/cell cycle regulation 
fzy CDC20 
Ubiquitin dependent 
protein catabolic 
process, cell cycle 
regulation 
Cell cycle regulation/ 
protein 
ubiquitination/ 
dendrite 
development 
S 
CG31639  
Ubiquitin-dependent 
protein catabolic process 
- 
S 
CG10973 HSPBP1 - 
Protein folding/ 
protein ubiquitinaton 
S 
mib2 MIB2 
Muscle cells 
homestasis/ubiquitin–
protein ligase activity 
Ubiquitin-protein 
ligase activity, Notch 
signalling pathway 
S 
CG9945 DCAF11 
Microtubule associated 
complex 
Protein 
ubiquitination 
S 
Lrr47 LRR1 
Ras protein signal 
transduction/ 
neurogenesis 
Protein 
ubiquitination 
S 
CG15253 - Proteolysis. - E 
CG5367 - Proteolysis - E 
CG8183 KIF13A Microtubule binding Protein transport E 
CG13423 - Proteolysis - S 
CG18735 - Proteolysis - S 
CSN1a - 
Regulation of G-protein 
coupled receptor protein 
signalling pathway 
- 
S 
ex - 
Protein binding/cell cycle 
regulation 
- 
S 
twe - Meiosis - S 
18w - 
Transmembrane 
signaling receptor 
activity 
- 
S 
Cell energy metabolism 
CG4701 - ATP binding - E 
CG9313 DNAI1  Motor activity E 
CG30093 - 
Cytochrome-c-oxidase 
activity 
 
E 
Vha26 ATP6V1E1  
ATP related proton 
transport. 
E 
Vha68-1 ATP6V1A  
ATP binding/ Proton 
transport 
E 
CG6870 -  
Electron carrier 
activity 
E 
CG5653 - 
Oxidation-reduction 
process/ oxidoreductase 
activity. 
- 
E 
Catsup SLC39A7 
Axon, synaptic vesicle, 
metal ion transport 
Transmembrane 
transport/ 
zinc ion transport 
S 
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Fas3 - 
Axon guidance/ synaptic 
target attraction and 
recognition 
- 
S 
Ptp69D  Axon guidance  S.L 
Metabolism 
CG9466 - 
Mannose metabolic 
process 
- 
S 
CG18284 - Lipid metabolic process - S 
CG3264 ALPPL2 Metabolic process Phosphorylation S 
CG5561 - Hydrolase activity - S 
CG10178 UGT2A3 
Glucuronosyltransferase 
activity 
Cellular 
glucuronidation 
S 
Dnz1 - Protein palmitoylation - S 
SamDC AMD1 - 
S-
adenosylmethionina
mine biosynthetic 
process 
S 
CG9406 EFCAB2 Calcium ion binding Calcium ion binding S 
CG9236 CIB2 Calcium ion binding 
Calcium ion 
homeostatis/ 
Photoreceptor cell 
maintenance 
S 
       Irk3 - 
Potassium ion 
transport/regulation of 
membrane potential 
- 
S 
Cytoskeltal related 
      CG10822  
 microtubule–based 
movement/dynein  
complex 
- 
 
 
 
          S 
Hip1 - Cytoskeltal organisation - S 
CG10674 WDR83OS - 
Integral to 
membrane 
S 
CG8370 TMEM131 - 
Integral to 
membrane 
S 
Misc. 
CG15168 MMGT1 - 
Magnesium ion 
transport 
S 
St4 SULT1C4 
Sulfation/sulfotransferase 
activity 
Sulfation 
/sulfotransferase 
activity 
S 
CG13994 - - 
Colocalises with 
protein 
phosphatase type 
1 complex 
S 
As indicated by Flybase. 
Drosophila gene as listed in Gene Database of NCBI. 
Human homologues according to HomoloGene Database. 
Modification of TDP-43 induced REP after GMR-Gal4-induced expression of shRNA. 
S- Suppression, E- Enhancement, L- Lethal, S.L Semi-lethal.  
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These candidates provided important insights into TDP-43 related pathways and 
biological functions. The identified candidates reconfirmed various other reports, which 
implied TDP-43 of being involved in RNA/DNA metabolism, protein binding, and 
neuron related processes. Interestingly, several candidates were found implicating 
towards the ubiquitin related UPS pathway substantiating our previous findings 
showing involvement of UPS pathway in TDP-43 related pathomechanisms.  
 In presented screening approach several candidates were found implicating 
TDP-43 function towards various biological pathways, however in the future step these 
needs to be further analysed in secondary assays (for example measuring their effect 
on TDP-43WT flies longevity or climbing, effect on aggregation and clearance 
mechanisms) and final validation in mammalian system has to be done. Nevertheless 
these candidates provide essential entry hints for further exploration in TDP-43 related 
neurobiology field. 
4.6 Yeast-2-hybrid screen- searching physical interactors 
In addition to genetic interactors, we set out to identify physical interactors of TDP-43. 
To achieve this, a yeast-2-hybrid screen was performed. It was decided to use TDP-
43∆NLS as “Bait”. All other TDP-43 variants displayed a nuclear (at least partially in case 
of TDP-43CTF) localisation, thus prohibited use in classical Yeast-2-hybrid screens. A 
human brain cDNA library served to generate the prey proteins. After the identification 
of 11 primary interactions hit, only one was found to be positive after high stringency 
screening (manufacturer’s screening protocol). 
The only identified interactor of TDP-43∆NLS was DBNDD2. DBNDD2 is also known as 
HSMNP1 (Hypothalamus protein 1), CK1BP (casein kinase 1 binding protein) or 
C20orf35. There is not much known about the function of the protein. Some data 
suggest that it is a paralogue of dysbindin and involved in lysosome biosynthesis that 
has been associated with schizophrenia and muscular dystrophy [113]. 
Further it has been shown that CKIBP is an isoform-selective binding partner of human 
casein kinase-1, may recruit casein kinase-1 isoforms to protein complexes involved in 
multiple biological function [113]. 
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Figure 34: Confirmation of DBNDD2 and TDP-43 interaction in yeast.  
Final confirmation of the interaction of DBNDD2 with TDP-43ΔNLS  (A, B) shows that only empty 
vector (pGBKT7, negative control) and DBNDD2 do not results in yeast colonies in QDO or 
DDO media however (C, D) TDP-43ΔNLS and DBNDD2 interacts resulting in growth of positive 
blue colonies on DDO media and highly stringent QDO media as well.  
QDO-Quadrouple dropout medium (Highly stringent media), DDO-Double dropout medium 
(medium stringent media). 
 
In a next step, it was tried to verify the DBNDD2 and TDP-43 interaction by co-
immunoprecipitation. To achieve this, HEK cells were co-transfected with vectors 
overexpressing DBNDD2 and TDP-43ΔNLS followed by immunoprecipitation procedure 
and visualised by Western blotting. Unfortunately, a physical interaction between TDP-
43 and DBNDD2 in HEK cells (mammalian system) was not confirmed given the 
available polyclonal antibody. The antibody is raised against a peptide mapping within 
an internal region of HSMNP1 of human origin. However it is imperative to check 
DBNDD2-TDP-43  interaction in future, with availability of more commercial antibodies. 
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5 Discussion 
TDP-43 was identified as a major protein component of neuronal inclusion 
bodies in the affected tissue in a range of neurodegenerative disorders collectively 
termed TDP-43 proteinopathies [3, 4]. Pathophysiological TDP-43 is characterised by 
decreased protein solubility, hyperphosphorylation, cleavage and cytoplasmic 
mislocalisation [3, 38]. Our transgenic flies recapitulated pathological and clinical 
features representing a powerful animal model for TDP-43 proteinopathy. 
5.1   Modelling TDP-43 proteinopathy in Drosophila melanogaster. 
  TDP-43 proteinopathies are characterised by TDP-43-positive inclusion bodies 
in affected neurons [3]. Based on available reports, both neurotoxic gain-of-function 
(GOF) and loss-of-function (LOF) mechanisms have been proposed for TDP-43 
proteinopathies and related neuropathologies [36]. Accordingly, the exact 
mechanism(s) leading to disease onset and progression is yet to be elucidated. The 
fact that endogenous TDP-43 functions remain elusive is adding complexity to the 
situation. Thus, TDP-43 researchers have dual challenges, first to understand 
endogenous functions of TDP-43 and secondly the role of TDP-43 in disease.  
   In order to gain insight into TDP-43 biology, an imperative step is to develop 
model systems. Since Drosophila melanogaster provides a simple yet highly efficient, 
genetically tractable system, Drosophila was chosen to analyse TDP-43 biology. 
Accordingly, flies overexpressing human TDP-43 were generated and characterised 
[41]. Several different TDP-43 variants: TDP-43WT representing native TDP-43, TDP-
43ΔNLS lacking nuclear localisation signal thereby representing cytoplasmic 
mislocalised TDP-43 and TDP-43CTF mimicking the main truncated version found in 
ALS patients were generated. The ubiquitous expression of TDP-43WT and TDP-43ΔNLS 
resulted in lethality, whereas TDP-43CTF did not; even in flies with markedly higher 
TDP-43CTF compared to TDP-43WT expression levels. This observation suggests that 
TDP-43CTF mediates low or no toxicity per se. 
               A negative correlation between expression strength of TDP-43WT and 
longevity (see Figure 13) after pan-neural induction of TDP-43 transgene was found. 
Our results show that the higher the expression of TDP-43WT, the shorter is the life- 
span of respective TDP-43 expressing flies. These results indicate that toxicity induced 
by TDP-43WT is dose-dependent.  TDP-43WT was found to be most toxic followed by 
CHAPTER 5 – DISCUSSION    76
TDP-43ΔNLS exhibiting medium toxicity and TDP-43CTF as least/non toxic (see Figure 
17). The detrimental effect of TDP-43 in different cell types was also analysed. One 
transgenic line with high expression of TDP-43WT caused lethality after pan-neural 
expression. However this line did not display a lethal phenotype after muscle or glia-
specific expression. This finding suggests that neuronal cells are specifically 
vulnerable to TDP-43 linked toxicity.  
         The subcellular localisation of three variants TDP-43WT, TDP-43ΔNLS and TDP-
43CTF in flies was further investigated. As expected, TDP-43WT was mainly observed in 
the nucleus whereas TDP-43ΔNLS and TDP-43CTF were cytoplasmically localised. Thus, 
TDP-43ΔNLS displayed efficient disruption of nuclear localisation as seen in pathological 
state. In addition, TDP-43CTF is representing the truncated variant of TDP-43, the main 
component of ubiquitin positive inclusions found in patients with TDP-43 proteinopathy. 
The TDP-43CTF (which lacks the NLS) was observed to localise in cytoplasm. These 
findings were consistent with cell culture based studies, showing similar behaviour of 
TDP-43WT TDP-43∆NLS and TDP-43CTF variants [114]. Moreover, our findings were 
confirmed by other groups, expressing these different TDP-43 variants in flies [42, 
115].  
Progressive and age-dependent neuronal loss is a major pathological hallmark 
of TDP-43 proteinopathy. In our study TDP-43WT expression resulted in neuron loss as 
seen by brain vacuoles and progressive deterioration of eye photoreceptors. These 
findings were also confirmed by other groups using similar fly models [108, 115, 116]. 
When TDP-43 was expressed specifically in motor neurons, age-dependent loss in 
motor function (locomotion) was observed. In summary, our fly model is able to 
recapitulate key phenotypes seen in ALS patients (see Figure 22).  
This data also clarified that the TDP-43 associated decline in longevity was not 
due to developmental defects. It was found that adult-onset expression of TDP-43WT 
also reduced life span. The reduction of the life span and loss of locomotor function are 
reminiscent of phenotypes closely related to the neurodegenerative process that 
indicates an alteration of either neuronal function, cell viability or both. 
     In patients suffering from TDP-43 proteinopathy, both abnormally 
phosphorylated full length TDP-43WT and TDP-43CTF are detected in affected neurons 
[3, 4, 20, 29, 67, 117-120]. These and other biochemical hallmarks of TDP-43 
proteinopathy could be recapitulated in our TDP-43 expressing flies. 
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 Western blot analysis after sequential extraction of soluble and insoluble 
fraction from total head protein lysates of TDP-43 expressing flies showed changes 
with age. Total head protein lysates from young flies (0-2 day post eclosion, dpe) 
contained mainly full length TDP-43 in the soluble fraction. In aged flies, however, the 
majority of TDP-43 was detected in the insoluble fraction. In addition, the insoluble 
fraction was found to be heavily phosphorylated and ubiqutinated. Moreover, a low 
molecular weight fraction in Western blot was observed. Although the exact length of 
these C-terminal TDP-43 fragments in flies cannot be determined, the separation 
revealed a fragment size of 25-27 kDa, highly reminiscent of TDP-43CTF observed in 
patients with TDP-43 proteinopathy. 
  
Table 13: Key features of the presented Drosophila melanogaster model. 
1) Our model recapitulates a wide range of neuropathological, biochemical and functional 
features of human TDP-43 proteinopathy. 
2) Overexpression of TDP-43WT leads to brain vacoulisation. 
3) This model can be used to study both sporadic and familial forms of TDP-43 
proteinopathy. 
4)  This model can be used to identify both genetic modifiers of TDP-43 toxicity and 
chemical compounds able to suppress or enhance TDP-43-induced rough eye 
phenotype (REP). 
 
During the course of presented study, several other groups also reported 
Drosophila models of TDP-43 proteinopathy. A systematic comparison of our and other 
fly models is provided in Table 14. The majority of the models recapitulate only a 
limited number of TDP-43 linked phenotypes. In comparison, our fly model 
recapitulates a large number of TDP-43 linked phenotypes making it an extremely 
useful model to investigate TDP-43 associated pathomechanisms. 
In summary, the fly model developed by us is a genetically tractable model, 
which recapitulates many aspects of TDP-43-induced neurotoxicity. It performs 
consistently in the majority of paradigms tested irrespective of embryonic onset or 
adult onset of TDP-43 expression. Our fly model displayed a wide range of 
neuropathological, biochemical and functional features of human TDP-43 induced 
proteinopathy. 
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Table 14: Systematic comparison of our Drosophila model with other fly models 
of TDP-43 proteinopathy. 
 
 Our model Other reported models 
                                                                            Transgenes 
 
Tagged 
Variable expression level 
TDP-43WT: GFP, TDP-43ΔNLS: GFP, 
TDP-43CTF: GFP 
- 
Untagged 
Same expression level 
TDP-43WT, TDP-43ΔNLS, TDP-43CTF, 
TDP-43FFLL, TDP-43A315T, TDP-
43A382T, TDP-43N390D, TDP-43G348C, 
TDP-43G287S 
TDP-43WT[108, 115, 116, 121],  
TDP-43CTD (lacking N-terminal RRM) 
[108],  
TDP-43NES* [115],  
TDP-43mNLS**[115],  
TDP-43M337V,  
TDP-43A315T [43] 
                                                                 Tissue-specific expression 
 
Eye Rough eye phenotype (REP) 
REP, Retinal toxicity [42, 108, 116]  
Axonal aggregates in developing 
eyes [43] 
Pan-neural 
Decreased life-span ranging from 
TDP-43WT<TDP-43NLS<TDP-
43MS<TDP-43FFLL<TDP-43CTF 
Decreased life-span [116, 122] 
Mushroom 
bodies 
Not analysed Axonal and neuronal loss [108] 
Motor neurons Decreased motor activity  
Aggregates in cell bodies and axons, 
axon swelling [108, 121] 
Age-dependent reduction in fly 
motility [108]  
Life span reduction [116] 
Glia Viable adults Pupal lethal [42] 
Muscles 
Viable but develop clapped/dropped 
wings, paralysis within 3-5 days 
followed by death 
Larval lethal [42] 
                                                                  Biochemical findings 
Biochemical 
changes 
Head extracts from aged flies show 
decreased solubility, insoluble 
fraction was phosphorylated and 
ubiquitinated, low molecular weight 
fragments were detected as well as 
high molecular weight forms were 
also seen.  
 
TDP-43 toxicity was found to be 
dose dependent. 
Abnormal phosphorylation of the 
disease-specific Ser409/Ser410 
residues, high molecular weight 
forms present [42]. 
 
 *NES - Nuclear export signal was mutated. 
**mNLS - Nuclear localisation signal was mutated. 
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5.2 TDP-43 mutants and their in vivo characterisation   
   Although there are various studies addressing the effect of TDP-43 toxicity and 
its disease-associated mutant variants, it is still unclear whether the mutations cause 
TDP-43 LOF or a toxic GOF effect [36, 42, 99, 115]. Variable disease mechanisms are 
being projected, however, there is no consensus on the origin of TDP-43 toxicity or 
toxicity-related mechanisms. In addition, the precise impact of missense mutations on 
aggregation and cleavage of TDP-43 in neuropathology remain unclear.  
Patients with TDP-43 proteinopathy display ubiquitin-positive, cytoplasmic 
inclusions as well as intranuclear inclusions [3]. The cytoplasmic TDP-43 inclusion 
formation is accompanied by substantial depletion of TDP-43 from the nucleus giving 
rise to the “LOF of nuclear TDP-43” hypothesis. Patients with disease-linked TDP-43 
missense mutations are indiscernible from sporadic patients with regard to disease 
onset, progression and pathology [33, 123]. However, some reports claimed the 
disease-linked mutations in TDP-43 mildly increase truncation [40], cytosolic 
mislocalisation [32] and aggregation [33] of the protein. All these effects have been 
correlated with increased cytotoxicity of TDP-43 [39] .  
In this study flies were generated, which expressed untagged variants of TDP-
43 to address the relative impacts of the missense mutations on TDP-43 related 
toxicity. In addition to the previously described TDP-43WT, TDP-43ΔNLS and TDP-43CTF, 
five disease-linked point mutations TDP-43A315T, TDP-43A382T, TDP-43N390D, TDP-
43G348C and TDP-43G382T were also generated and their effects on TDP-43 related 
toxicity was investigated.  
In relation to the toxic effects of TDP-43WT, all mutant TDP-43 variants were 
found to be less toxic. These data are inconsistent with some published studies 
suggesting a simple GOF effects induced by TDP-43 missense mutation and/or 
truncation [38, 43, 69, 91, 124, 125]. In such a scenario, it would have been expected 
that the mutant TDP-43 variants to be more toxic compared to TDP-43WT. Previous 
results were derived mostly from cell culture based studies with transient or stable 
transfected cells. In presented analysis, the site-directed insertions of the transgenes 
resulted in similar/same expression levels of the different TDP-43 variants [41]. The 
lack of tightly controlled expression levels might be the reason for the differences in 
toxicity reported by other groups. Such tightly controlled expression levels are of vital 
importance, as a clear dose-dependency of TDP-43-induced toxicity was seen. 
Moreover, our data was supported by in ovo analysis using chick embryos [41, 43, 91]. 
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Here, motor neuron-specific expression of different TDP-43 variants exerted the same 
toxic effects as observed in flies (see Figure 21). TDP-43WT was the most toxic variant 
followed by amino acid substitution variant TDP-43A315T and cytoplasmic localised 
TDP-43∆NLS. The least toxic variant was TDP-43CTF. Based on our observation; we 
suggest a general toxic GOF mechanism upon TDP-43 expression. This would explain 
TDP-43 toxicity in our overexpression experiments. The lower toxicity of mutant 
compared to wild-type TDP-43 suggested that the TDP-43 missense mutations 
represent weak LOF alleles. In this scenario, the missense mutations in TDP-43 might 
cause a partial depletion of TDP-43 function(s). All these effects will limit the GOF 
effects by TDP-43. 
However, the fact that depletion of TDP-43 is lethal in multiple organisms (mice, 
fish and flies) implied a fundamental role of the protein at least in development [126-
128]. In disease situation, TDP-43 is localised in cytoplasmic inclusions and depleted 
from the nucleus [3, 119]. This raised the idea that a loss of nuclear TDP-43 (function) 
might be causative for disease. The lower toxicity of mutant TDP-43 in an 
overexpression situation is in agreement with this assumption.  
In cell culture systems low levels of toxicity are often not evident, as cells are 
not cultured long enough. Moreover, TDP-43 abundance is tightly controlled in a 
feedback loop. TDP-43 binds its own mRNA and thereby blocks its translation [95, 
129]. Consequently, it was asked whether the detrimental effect of exogenous TDP-43 
expression could result from interference with endogenous fly TBPH, the Drosophila 
homologue of TDP-43. A recent study reported that TDP-43/TBPH levels are critical 
determinants of neurotoxicity in flies [96]. It was found that TDP-43 expression is not 
altering TBPH abundance, neither on protein nor on mRNA levels (see Figure 23). 
Next it was attempted to see whether the TDP-43-mediated phenotypes could be 
rescued by silencing expression of TBPH via RNAi. By silencing TBPH expression, the 
lethal phenotype observed after strong pan-neural expression of TDP-43WT could not 
be rescued. However, silencing TBPH caused an increase in life-span in combination 
with a moderately TDP-43 expressing fly line, indicating a potential interaction between 
RNAi-mediated silencing of TBPH expression and TDP-43 induced toxicity. 
In another approach the TDP-43-induced REP was used as readout. The REP 
has been proven to be suitable to detect enhancers and suppressors. Using the 
TBPH[null] allele, a robust suppression of the REP induced by expression of TDP-43 
was not  detected  [98]. Although a subtle suppression of the REP was identified, this 
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was not as strong as effects observed for other genes (our screen candidates). 
Therefore, a more detailed analysis is needed to draw conclusions about possible 
genetic interactions is required. 
 In summary, our findings again highlight the point that while comparing different 
forms of TDP-43, it is very important to control relative protein expression levels. 
Accordingly, less overt variant-specific differences in toxicity could consequently be 
masked, or misrepresented, by varying TDP-43 concentrations such as achieved by 
random insertion trangenesis. For example, low TDP-43WT expression levels had only 
mild impact on longevity, while high levels of TDP-43WT resulted in marked reduction of 
life-span. Moreover, while the random-insertion transgenic lines displayed clear 
differences between impacts on overall viability induced by TDP-43WT and TDP-43CTF 
expression, more subtle differences between TDP-43WT and TDP-43ΔNLS obvious in 
our site-specific trangenes (similar expression) were not resolved. Previous difficulties 
in normalising toxicity to relative protein levels could therefore account for conflicting 
results separately showing toxic effects by either wild-type, or ALS/FTLD-linked mutant 
TDP-43. 
5.3 TDP-43-mediated neuron loss in vivo requires RNA-binding activity. 
        TDP-43 was initially identified as a splicing regulator that specifically binds to 
(UG)m repeats [47]. Burrati et al. explored the RNA-binding properties of TDP-43 and 
confirmed existence of two fully functional RNA recognition motifs (RRM1 and RRM2) 
[51]. It was further suggested that the RNA-binding characteristics might be involved in 
the disease-causing mechanism(s) in vivo [51]. To investigate whether RNA-binding 
function is crucial for TDP-43-mediated neurotoxicity, two missense mutations 
(F147L/F149L) were introduced in RRM1 to abolish inherent TDP-43 RNA-binding 
function. We showed that TDP-43 RNA-binding activity seems to be essential for TDP-
43-mediated toxicity in Drosophila. Interestingly, similar to TDP-43CTF, chronic 
expression of the RNA binding-deficient variant TDP-43FFLL did not result in toxicity as 
compared to TDP-43WT. However, it was found that  TDP-43FFLL was slightly more 
toxic than TDP-43CTF as evident from life span and climbing analysis. Accordingly, the 
toxicity range was TDP-43WT> TDP-43ΔNLS> TDP-43FFLL> TDP-43CTF. TDP-43CTF is 
entirely lacking the RRM1 and partially lacking RRM2, which should abolish RNA-
binding completely. Thus the elevated toxicity of TDP-43FFLL in relation to TDP-43CTF 
could be explained by a potential residual RNA-binding activity in TDP-43FFLL. This 
observation substantiates a requirement of TDP-43 RNA-binding activity for TDP-43 
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mediated toxicity in vivo. It might be speculated that TDP-43WT is binding to a particular 
unknown target gene(s) to exert observed toxicity and subsequent neurodegeneration 
in our fly model.  
Supporting our findings, two other studies suggested that RNA-binding protein function 
could be central to TDP-43-related neurodegeneration in mice [130] and flies [131]. 
The link between TDP-43 RNA-binding activity and manifestation of neurotoxicity in 
ALS/FTLD is not known, but increasing evidences show that TDP-43 plays a very 
significant role in RNA metabolism and much effort has been done to identify neuronal 
RNA targets of TDP-43. These efforts further led to the discovery of other RNA-binding 
proteins like of FUS/TLS [132] .  
       TDP-43 and FUS have structural and functional similarities. As both proteins bind 
and process RNA, it was suggested that RNA-binding might be one of the major 
biological phenomena involved in disease progression [9, 37, 133, 134]. In fact, TDP-
43 was identified as a regulator of essential transcriptional events in the CNS [135]. In 
our TDP-43 screen for modifiers of TDP-43-induced toxicity, we found that the majority 
of candidates can be grouped under the term “DNA/RNA-related functions”. Combining 
our results with recent findings, it is suggested that investigating TDP-43 RNA-binding 
function(s) and TDP-43’s role in RNA metabolism could lead to a better understanding 
of TDP-43-mediated toxicity.   
Table 15: Key findings. 
 
1. TDP-43 toxicity is dose-dependent. TDP-43/ TBPH total levels seem to influence 
neurotoxicity. 
 
2. Elicitation of neural defects by TDP-43 expression appeared to be independent from 
ALS/FTLD-linked mutation, truncation, or mislocalisation, all of which appeared to at 
least slightly reduce impacts caused by equal expression of TDP-43WT. 
 
3. Equalised TDP-43 protein expression levels in Drosophila revealed a requirement for 
inherent TDP-43 RNA-binding activity for eliciting neural defects. 
 
 
 
5.4 Genome-wide screen for TDP-43 modifiers 
To gain more insights in the cellular mechanisms involved in TDP-43 induced toxicity, 
a genome-wide screen was conducted as discussed below in detail. 
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5.4.1 The conducted screen  
In flies, genome-wide screens are commonly used and turned out as efficient 
tools to identify genetic interactions [136]. In the context of human diseases, the fact 
that roughly 75% of human disease associated genes have orthologues in flies implies 
a significant conservation of biological pathways between flies and humans [137-140].  
The genome-wide screen for modifiers of TDP-43 induced toxicity performed in 
this study is unique since this study directly addressed neurotoxicity using the REP as 
readout. TDP-43 inclusions are neuropathological hallmarks of ALS and FTLD-U, but 
there is a multitude of unanswered questions regarding TDP-43 inducing neurotoxicity, 
TDP-43’s interaction with cell signalling pathways and its inherent endogenous 
functions. Presently, some studies are available on TDP-43 genetic modifiers utilising 
yeast [141] and cell based approaches [96, 142]. In present study, I tested deficiencies 
lacking a defined chromosomal region to modify the TDP-43-induced REP. Using the 
deficiencies, all autosomal genes for enhancers and suppressors of TDP-43 toxicity 
were screened. After validation, verification and single gene analysis, 67 genes were 
identified to modify the TDP-43-induced REP. The specificity of candidates was 
analysed by testing their ability to modify REPs induced by the expression of other 
neurotoxic proteins or peptides (Tau, PolyQ, Aβ42). Those candidates, which 
commonly modified the REPs, were excluded from the final candidates list. The 
resulting TDP-43 specific modifiers were then assigned to distinct groups reflecting 
their involvement in biological pathways (see Table 12).  
5.4.2 Comparison with other TDP-43 screens 
Since the discovery of TDP-43 in ALS and FTLD and other neurodegenerative 
disorders, many approaches were taken to elucidate TDP-43’s interacting partners, 
targets and toxicity modifiers. Several common themes have emerged from all of these 
studies. There is a consensus on TDP-43 being involved in gene regulation 
(transcription, splicing, translation) [143] and neuronal integrity [144]. An overview of 
the conducted screens and a brief summary of the main results are provided in Table 
16.  
Thus, screen candidate modifiers of the TDP-43-induced REP are likely not only 
contribute to TDP-43 toxicity in flies but might also contribute to the pathology in TDP-
43 proteinopathies.  
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Table 16: An overview of TDP-43 related screening approaches. 
This table summarises the various screen strategies employed in various model systems and 
their major findings. 
 
TDP-43 modifiers/ 
proteomic partners 
Method Findings Reference 
                                                   Screening approaches   
Screen to explore factors 
that regulate the nuclear 
import of TDP-43.  
 
 siRNA library for 
gene coding for 82 
proteins involved in 
nuclear transport 
screened. 
Knockdown of karyopherin-β-1 
and cellular apoptosis 
susceptibility proteins resulted 
in marked TDP-43 cytoplasmic 
accumulation. 
[178] 
Screen to identify 
pathways controlling 
TDP-43 
nucleocytoplasmic 
shuttling.  
High-content 
genome-wide RNAi 
screen. 
60 genes identified whose 
silencing increased the 
cytosolic localisation of TDP-
43 including nuclear pore 
complex component, 
regulators of G2/M cell cycle 
transition. ITPR1 was 
identified as a strong 
modulator.  
[142] 
Screen to identify TDP-
43-specific kinases. 
Biased 
comprehensive 
RNAi screen. 
CDC7 was identified 
phosphorylating TDP-43 at 
S409/410 residues. 
[179] 
                                            Identifying gene expression changes   
 Understanding the 
relationship between 
TDP-43 misregulation and 
neurotoxicity. 
Gene expression 
pattern change with 
TDP-43 over- 
expression. 
Strong upregulation of cell 
cycle regulatory genes and 
genes functioning in Notch 
intercellular communication 
pathway. 
[96] 
                                             Neuronal RNA target / protein interactors  
  Identification of neuronal 
RNA targets of TDP-43 
and physiological protein 
partners.  
RNA-IP followed by 
deep sequencing. 
Targets particularly rich in GO 
terms like synaptic function, 
RNA metabolism, neuronal 
development, pre-mRNA 
splicing, RNA stability and 
transport. 
[48, 49] 
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 Identification of proteins 
regulated by TDP-43. 
Global proteomic 
approach. 
Extensive interaction with 
proteins that regulate RNA  
metabolism, two distinct 
interaction networks (a) 
nuclear /splicing cluster (b) 
cytoplasmic/ translation 
cluster. 
[45] 
                                                           Microarray in cell lines  
Analysis of transcript 
change following TDP-43 
depletion using siRNA 
(HeLa Cells) 
Microarray. Transcripts related to pRB 
pathway (retinoblastoma) 
involved in cell cycle, cellular 
differentiation, other transcripts 
related to cell cycle control. 
[52] 
Analysis of transcript 
change following TDP-43 
depletion using siRNA 
(HEK Cells)  
Microarray. HDAC6 transcript and protein 
as major direct target of TDP-
43, HDAC6 protein is known to 
control protein aggregate 
formation and degradation. 
[98] 
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5.4.3 Biochemical pathways implicated in TDP-43 related neurotoxicity 
  To gain further insights into the potential mechanisms involved in TDP-43-
mediated toxicity, screen candidate genes were assigned to distinct functional groups. 
The grouping was based on biological information available on various databases for 
example NCBI (http://www.ncbi.nlm.nih.gov), Fly base (http://flybase.org) and 
published literature. This led to the identification of several biological pathways and 
mechanisms, which could be involved in TDP-43 toxicity, briefly discussed below. 
Recently, several studies identified RNA targets of TDP-43, rich in Gene 
Ontology (GO) terms like synaptic function, RNA metabolism and neuronal 
development implicating that alterations in TDP-43 abundance might cause a 
dysregulation of the RNA metabolism, eventually contributing to neurodegeneration 
[48, 49, 145-147]. Our screen candidates can be grouped in these central themes, 
reassuring the role of TDP-43 in these biological areas. In fact the biggest subgroup of 
the candidates is “DNA/RNA related gene products” in presented screen. TDP-43 is 
already known as splicing regulator and has multiple roles in the regulation of gene 
expression [36, 50, 143, 148-151]. Candidates involved in splicing, transcription 
regulation and nucleic acid binding were found. Among these were: CG2931 (RBM42), 
mago, noi, CG5343 and CG4887. Interestingly many of these candidates enhanced 
TDP-43-induced REP suggesting that these genes are involved in, or with TDP-43 
related spliceosome regulation. Finding these new candidates corroborate the finding 
that TDP-43 has multitude of targets and associated proteins. It has already been 
shown that TDP-43 exists in high molecular mass ribonucleoprotein complexes that 
are dependent on the presence of nucleic acids [135]. Furthermore, many of the 
proteins associated with TDP-43 in these complexes are involved in pre-mRNA 
splicing, RNA stability and transport [135, 145, 152]. This is of vital importance, as loss 
of spliceosome integrity is suggested to be a critical mechanism in ALS [153].  
Further found two candidates involved in histone modification were found. 
Histone methylation and demethylation is a critical process for the regulation of gene 
expression. These candidates were Utx and Sap130. Utx and its human homologue 
KDM6A have histone demethylase activity [154]. Another candidate, Sap130  (whose 
human homologue SAP130) is a subunit of the histone deacetylase-dependent SIN3A 
corepressor complex, thus contributing to histone deacetlytransferase activity [155]. 
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Apart from the candidates described above transcription factors or other nucleic acid 
binding proteins were also found (see Table 12). 
My screen candidates are in line with recent reports providing evidence and 
strongly establish the importance of TDP-43 in RNA metabolism and gene regulation 
[41, 49, 143, 145]. Although there is no distinct link or evidence found how this 
interaction leads to neurodegeneration, these findings paved the way for RNA 
processing as an ideal field to look further as one of the pathomechanism underlying 
TDP-43-induced neurodegeneration. 
The second major theme, which emerged from this screen, were genes that 
code for proteins involved in the ubiquitination proteasomal pathway. Ubiquitination is 
a post-translational modification process in which the small regulatory protein Ubiquitin 
gets attached to a substrate protein. Ubiquitination can direct the substrate protein for 
degradation via the proteasome, alter its cellular location or affect its interaction with 
other proteins [99]. Ubiquitination of TDP-43 seems to be altered in TDP-43 
proteinopathies, since pathological TDP-43 is heavily ubiqutinated in patients [3]. In 
our screen several candidates coding for proteins implicated in Ubiquitin proteasomal 
system (UPS) were also found. Among those are candidates like Cand1, fzy, 
CG31639, CG10973, mib2, CG9945 and Lrr47.   
The candidate fizzy (fzy) is involved in cell cycle regulation, proteasomal 
ubiquitin-dependent protein catabolic processes and neurogenesis [156]. Its human 
orthologue CDC20 (cell cycle division cycle 20) acts as a regulatory protein interacting 
with several other proteins at multiple points during the cell cycle [157]. CDC20 is 
required for two microtubule-dependent processes, nuclear movement prior to 
anaphase and chromosome separation. It has been shown that TDP-43 mediates 
neurite outgrowth through HDAC6 [158] and HDAC6 in turn regulates dendrite 
morphogeneisis in post- mitotic neurons by acting on anaphase promoting complex 
and CDC20 at centrosome [159]. Since HDAC6 is a well-known interactor of TDP-43 
[98, 152, 158, 160], it can be speculated that TDP-43, HDAC6 and CDC20 work in 
concert in the formation and/or maintenance of dendrites. Thus, alterations in these 
interactions could destabilise dendrites. This in turn might alter neuron function and 
reduce survival of affected neurons. 
Another candidate Cand1 is involved in protein/transcription factor binding and 
negatively regulates protein neddylation [161]. Neddylation is analogous to the 
ubiquitination process in which an ubiquitin-like protein Nedd8 is conjugated to its 
CHAPTER 5 – DISCUSSION    88
target protein. The human orthologue CAND1 is involved in transcriptional regulation 
and protein ubiquitination and part of the ubiquitin ligase complex. Again we found the 
UPS-related candidate indicating the crosstalk between TDP-43 and UPS pathway. 
Similarly another candidate gene CG31639 is predicted to have ubiquitin thiolesterase 
activity and involved in ubiquitin-dependent protein catabolic processes (flybase) 
reiterating the connection between TDP-43 and the UPS pathway.  
Identifying the candidate CG10973 further supports this assumption. The 
function of the encoded protein is unknown in Drosophila, however its human 
orthologue HSPBP1 ((heat shock 70kDa) binding protein, cytoplasmic cochaperone1 
[Homo sapiens (human)]) is involved in positive regulation of protein 
ubiquitination/proteasomal ubiquitin-dependent protein catabolic process [162]. 
Another candidate mib2 (mind bomb 2) is involved in muscle cell homeostasis and has 
predicted ubiquitination-protein ligase activity (flybase). The same is true for its human 
orthologue MIB2 (mindbomb E3 ubiquitin protein liagse 2) involved in Notch signalling 
and also has ubiquitin-protein ligase activity [163]. Recently, strong upregulation of 
genes functioning in Notch intercellular communication pathway was identified after 
constitutive eye-specific expression of TDP-43WT in Drosophila in a microarray-based 
study [96]. Another candidate pointing towards the Notch signalling pathway was 
found, namely ebi (human orthologue TBL1X). TBL1X is involved in many functions 
like signal transduction, RNA processing, gene regulation and vesicular trafficking 
[164, 165] 
Ubp64E and also its human orthologue USP47 is an ubiquitin-specific peptidase 
[166-168]. USP47 regulates DNA repair and maintains genome integrity [167]. It also 
plays a crucial role in controlling axonal growth during neuronal development [169]. 
Interestingly, USP47 has been identified as target of FUS in two studies [146, 170]. 
TDP-43 and FUS belong to same class of ribonucleoproteins. They have structural as 
well as functional similarities and both proteins have an established role in ALS and 
FTLD. Although TDP-43 and FUS have distinct functions they work together in a 
common genetic pathway [55].  
My results suggest that the UPS pathway might be involved in mediating TDP-
43 related toxicity. The detailed investigation of UPS pathway with respect to TDP-43 
clearance showed, that the UPS is the primary pathway involved in TDP-43 clearance 
(see Figure 26). 
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Pathological TDP-43 is abnormally truncated. It has been shown that chronic 
stabilisation of TDP-43WT provoked cytotoxicity and recapitulated pathogenic protein 
cleavage and insolubility [171]. The fact that TDP-43 is truncated is well reported but 
how TDP-43 truncation contributes to disease progression is still under investigation. 
The enzymes responsible for TDP-43 proteolytic processing in human brain remain 
largely unknown. The only enzyme reported to cleave TDP-43 is asparaginyl 
endopeptidase (AEP). A recent study confirmed AEP cleaving TDP-43 at seven sites 
and Western blots of brain homogenates isolated from AEP[null] mice and wild-type 
littermates controls revealed that TDP-43 proteolytic fragments were substantially 
reduced in the absence of AEP in vivo [172]. However, Drosophila lacks a clear 
othologue of AEP. Nevertheless, in our screen, several peptidases were found for 
example aminopeptidase CG10576 and endopeptidases like CG15253 
(Metalloendopeptidase), CG5367 (Cysteine-type endopeptidase), CG13423 (cysteine-
type endopeptidase), CG18735 (serine type endopeptidase). Further investigation of 
these peptidases will help to understand TDP-43 truncation mechanisms and thereby 
role of TDP-43 truncation in the disease pathomechanism. One of the candidates, 
CG10576 is reported to have aminopeptidase activity whereas its human orthologue 
PA2G4 encodes for RNA-binding protein. PA2G4 is present in pre-ribosomal 
ribonucleoprotein complex and involved in ribosome assembly, regulation of ribosomal 
processing and cell cycle regulatory genes through its interaction with HDACs. In 
addition PA2G4 is also involved in ubiquitin protein ligase binding [173].  Interestingly, 
PA2G4 was also identified to interact with TDP-43 and could alter kinase signalling 
that accelerates assembly to elF2-RNA binding-ribosome preinitiation complex thereby 
modulating the translation rate of some mRNAs [174]. It is important to note that many 
candidates fall under more than one group suggesting multifunctional role of these 
candidates and thereby influencing TDP-43 in more than one way. In the next step it 
should be ascertained how these candidates influence TDP-43 cleavage in more 
advanced experimental set up. 
The next theme, which emerged in presented screen, was synapse-related 
candidates.  A local spatio-temporal control of protein synthesis is required given the 
complexity of neuronal subcellular domains [144]. The synthesis of many synaptic 
proteins is under local control of mRNA binding proteins which function as key 
regulators of local RNA translation [144]. This regulation mostly occurs via RNA 
granules, which are based on reversible aggregation of RNA binding proteins (RBPs) 
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such as TDP-43. TDP-43 was found to be present in RNA granules in dendrites and 
functions as a synaptic activity responsive factor; localisation of TDP-43 at dendritic 
spine is highly regulated by neuronal activity [53, 144]. Supporting recent findings we 
discovered several candidates indicating synapse-related functions for example 
Catsup, Fas3, Ptp69D. The human homologue of Catsup, SLC39A7, codes for zinc 
transporter, which is very important for activation of tyrosine kinases [175]. Fas3 is 
involved in axon guidance, synaptic target recognition and cell structure integrity [176, 
177]. Ptp69D is a protein tyrosine phosphatase, which is involved in motoneuron axon 
guidance. In line with these results, recent studies identified large number of neuronal 
transcripts linked to synaptic functions whose splicing is affected by TDP-43.  
 In the future, the candidates identified in this study need further characterisation 
to gain insights into TDP-43 related mechanisms. They provide excellent entry points 
to analyse biological pathways, which could be important in TDP-43 biology. 
5.4.4 Concluding remarks on conducted screen 
The presented screen for TDP-43 toxicity modifiers shortlisted several 
interesting areas for further exploration to understand TDP-43-related toxicity and 
disease mechanisms. The major theme that emerged from this screen candidate is 
nucleic acid related genes. We identified candidate genes controlling gene expression 
at multifunctional levels for example chromatin remodelling, transcription and RNA 
splicing indicating the importance of RNA metabolism and the putative role of TDP-43 
in relation to them. In fact, there is now accumulating evidence highlighting the 
importance of RNA metabolism dysregulation and its implications in 
neurodegeneration. Many more genes are now being implicated in the ALS-FTLD 
spectrum, which play an important role in RNA homeostasis for example FUS/TLS 
[180, 181], ANG [182] and SETX [183]. We have already shown that the RNA-binding 
function of TDP-43 is essential to impart toxicity in fly. Recently, a number of 
approaches have been taken to uncover interacting partners of TDP-43 resulting in an 
interesting spectrum of RNA interacting proteins [145] [48, 49].  
The multitude of TDP-43 targets makes it difficult to decide which of them might be 
most important for disease pathology. However, our screen provides interesting 
insights and helps to streamline further research on TDP-43-induced toxicity. 
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5.5 Clearance mechanism of TDP-43 
The Ubiquitin proteasomal system (UPS) and autophagy are two major protein 
quality control mechanisms in eukaryotic cells [184]. Dysfunction in both, UPS and 
autophagy has been discovered in neurodegeneration, for example in AD [185], PD 
[186, 187] and Huntington disease [188]. In fact, an extensive crosstalk between these 
two degradative pathways is observed [185]. Similarly, both of these mechanisms are 
also being implicated in TDP-43 proteinopathies [72, 101, 102, 116, 189]. However, 
presently available data could not clarify whether dysfunction of either clearance 
mechanism contributed to TDP-43 pathology. Moreover, it is still not clear whether 
TDP-43 accumulations are permanent structures or actually can be cleared by 
autophagy and/or UPS. To get more insights in these questions both mechanisms 
were studied in flies expressing TDP-43. 
Cell culture-based studies have shown a synergistic role of the proteasome and the 
autophagosome in clearance of poly-ubiqutinated TDP-43 [99, 104, 190]. One study 
shows that autophagic markers L3-11 and p62 were found to be increased in spinal 
cord of both ALS patients and experimental models indicating overwhelmed 
autophagic level and suggested aggregation could lead to insufficiency of autophagic 
induction [191]. Another study shows that inhibition of either proteasome or autophagy 
dramatically increases TDP-43 aggregation [99]. TDP-43 aggregates co-localise with 
markers of autophagy and the poly-ubiquitin binding adaptor protein p62/SQSTM1. 
Over-expression of p62/SQSTM1 reduces TDP-43 aggregation in an autophagy and 
proteasome dependent manner [192]. In cultured primary neuronal cells proteasome 
inhibition induced significant cytoplasmic accumulation, accompanied by 
phosphorylation, ubiquitination and aggregation of TDP-43 [100]. It has also been 
shown that inhibition of mTOR, a key protein involved in autophagy regulation reduces 
TDP-43 25kDa CTF accumulation. Rapamycin is a selective inhibitor of mTOR protein, 
thus rapamycin administration induces autophagy. It has already been shown that 
autophagy activation by mTOR inhibitors has beneficial effects in neurodegeneration 
[188, 193]. For example, the administration of rapamycin at an early pathological stage 
to a mouse model with FTLD-U could rescue the learning and memory deficiency and 
the abnormal motor function of mice [104]. Moreover, autophagy activation at a late 
pathological stage also improves motor function, which was accompanied by a 
reduction of TDP-43 positive UBIs [104]. Administration of rapamycin in a TDP-43 
expressing mouse cell line (neuro2 A) and in a human neuroblastoma cell line (SH-
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SY5Y) rescued TDP-43 induced toxicity [191]. Our data shows that rapamycin treated 
TDP-43 expressing flies showed increased life-span as compared to non-treated flies 
implicating autophagy activation has a beneficial effect on TDP-43 toxicity on flies. 
However, when we silenced expression of autophagy-related genes via RNAi and 
observed REP modulation in GT flies, we found only mild or no impact on the REP. On 
the other hand constitutive expression of downstream components of mTOR signalling 
pathway dramatically enhanced the REP of GT flies. Along with autophagy, mTOR 
pathway also regulates local RNA translation at the synapses. Thus it is suggested 
that abnormal translational control could enhance TDP-43-related toxicity. It has been 
shown the local regulation of protein synthesis in neurons is very important for synaptic 
plasticity and in neurological diseases [144]. Moreover, TDP-43 and other RNA-binding 
proteins are key regulators of this local RNA translation [144].  
Presented data on TDP-43 supports its involvement in translational regulation. 
Further, inhibition of autophagy in TDP-43WT expressing flies by crossbreeding them 
with a fly line containing dominant negative allele PI3K (Phosphatidylinositol 3-kinases 
inhibits autophagy by blocking autophagosomes formation) resulted in enhanced TDP-
43 induced REP (see Figure 29). However, genetic silencing of autophagy genes had 
no effect on REP (see Figure 30). The observed REP enhancement might be 
explained by PI3K acting upstream of mTOR pathway. Thus, an enhancement of the 
REP might be due to the interference of PI3K with the mTOR pathway, rather than its 
inhibition of autophagy.  
Simultaneously, I also investigated the role of UPS in TDP-43 clearance. It was 
found that the TDP-43CTF is degraded by the proteasome in vivo (see Figure 25). This 
is in line with findings by another study, in which inclusions formed by TDP-43CTF were 
reported to be cleared through UPS [72].  
  It was further observed that the systemic proteasome inhibition by MG-132 
administration caused early lethality in TDP-43 expressing flies and that TDP-43 levels 
increased (see Figure 26). Moreover, targeted knockdown of proteasome subunits 
consistently enhanced REP of the GT flies. I also observed proteasomal stress in eye 
discs after TDP-43WT expression indicating, in the overexpression background of TDP-
43, the UPS is impaired and/or dysfunctioning (see Figure 26) [81].  
In summary, these results show that UPS is the primary pathway for degradation 
of TDP-43. These findings imply that UPS is playing a crucial role in TDP-43 
metabolism and its dysfunction could be another contributing factor in TDP-43-related 
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pathomechanisms. Studies have recognised an impairment of protein degradation 
machineries to participate in motor neuron degeneration in ALS and several others 
neurodegenerative disorders [194-201]. Consistent with our results, impairment of 
protein degradation via the proteasome has been shown to recapitulate pathogenic 
TDP-43 hallmarks in various other experimental systems [102, 171, 194]. The 
enhancement of proteasome activity may be a promising therapeutic strategy for the 
treatment of TDP-43 proteinopathies. 
6  Concluding remarks 
  Although already first described in 1995 by Ou et al. [44], TDP-43 was linked to  
neurodegeneration by Neumann et al. in 2006 [3]. TDP-43 was identified as the major 
protein component of inclusions that are characteristic of most forms of ALS and 
FTLD. Since this discovery, more than 30 different mutations have been identified in 
TDP-43. In addition, TDP-43 inclusions have been reported in other diseases as well 
[5, 202-205]. Pathological TDP-43 is mislocalised and accumulates abnormally in 
phosphorylated, ubiquitinated inclusions in the cytoplasm. Whether TDP-43-induced 
neurotoxicity is due to gain of cytoplasmic function or loss of nuclear function is still not 
clear. Relatively new, not much is known about TDP-43 endogenous functions, protein 
partners and targets. There are several open questions that need to be answered to 
address impending pharmacological interventions to cure TDP-43 proteinopathies. The 
presented study focussed on elucidating TDP-43 related toxicity. It was found that the 
endogenous function of RNA- binding is essential to impart TDP-43 toxicity. Moreover, 
It was shown that the disease-linked mutations in TDP-43 have reduced toxic effects 
compared to the wild-type protein in vivo. In the end this study suggests that disease 
linked mutations in TDP-43 represent rather partial LOF than toxic GOF alleles. 
 Further several modifiers of TDP-43-induced toxicity through an unbiased genetic 
screen were identified. Here, the importance of tightly controlled RNA-binding and 
protein degradation pathways in TDP-43 proteinopathy was highlighted. The novel 
candidates provide entry points to investigate TDP-43-induced pathogenic 
mechanisms and pathways to human disease.    
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Appendix 
 
Appendix Table 1 : REP observerd for Single gene candidates. 
Transformant 
ID (Fly lab 
database 
number) 
Gene name CG number 
REP 
modification 
Phenotype 
13245 (#0635) CG6201 CG6201 E N.A 
22015 (#0892) CG5142 CG5142 E 
 
31023 (#0938) CG18301 CG18301 E 
 
8710 (#1087) CG10257 CG10257 E 
 
34368 (#1181) CG7180 CG7180 E N.A 
2777 (#1569) CG4972 CG4972 E N.A 
8797 (#2176) CG8320 CG8320 E 
 
28386 (#2423) 
spalt-related 
(salr) 
CG4881 E 
 
Appendix 
 
20946 (#2622) CG2931 CG2931 E 
 
40862 (#3135) ebi CG4063 E  
31388 (#3327) CG10948 CG10948 E 
 
10756 (#3601) 
47182 (#4648) 
ventral veins 
lacking (vvl) 
CG10037 E  
 
40565 (#3804) CG4957 CG4957 E 
 
9763 (#4145) CG4701 CG4701 E 
 
3879 (#4827) CG5755 CG5755 E  
 
26685 (#5889) 
Selenophosph
ate synthetase 
2 (Sps2) 
CG5025 E 
 
Appendix 
 
29099 (#6660) CG9313 CG9313 E 
 
23028 (#6677) 
Kinesin-73 
(Khc-73) 
CG8183 E 
 
17893 (#7145) CG30093 CG30093 E 
 
30729 (#7362) CG15253 CG15253 E 
 
12618 (#7495) 
Replication 
factor C 38kD 
subunit 
(RfC38) 
CG6258 E 
 
37591 (#7825) Snm1 CG10018 E 
 
49534 (#7612) 
29054 (#6661) 
CG9154 
CG9154 
 
E  
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12392 (#7750) CG5367 CG5367 E  
 
45374 (#1329) 
Vacuolar H+-
ATPase 26kD 
E subunit 
(Vha26) 
CG1088 E  
 
44325 (#1737) pixie (pix) CG5651 E  
 
17102 (#5128) 
46397 (#1756) 
Vha68-1 CG12403 
E  
 
 
28132 (#7164) 
mago nashi 
(mago) 
CG9401 E  
 
52570 (#5968) CG6870 CG6870 E  
 
20826 (#5069) Regena (Rga) CG2161 L - 
46133 (#2190) CG10080 CG10080 E N.A 
3801 (#5126) CG11110 CG11110 E N.A 
20943 (#1814) noisette (noi) CG2925 SL N.A 
Appendix 
 
4789 (#3978) 
942 (#5110) 
27090 (#5356) 
Protein 
tyrosine 
phosphatase 
69D (Ptp69D) 
CG10975 
E  
 
 
6541 (#7132) 
39176 (#7805) 
Toll-7 CG8595 
S  
 
 N.A 
50152 (#6551) CG31792 CG31792 S  N.A 
48622 (#0059) 
31791 (#2096) 
CG13994 CG13994 
S  
 
 
8972 (#0067) 
46760 (#2212) 
CG8297 CG8297 
S  
 
 
965 (#0176) 
36305 (#1948) 
44386 (#3695) 
18 wheeler 
(18w) 
CG8896 
S  
 
 
39418 (#0334) 
29733 (#0763 ) 
33803 (#4896) 
S-
adenosylmethi
onine 
decarboxylase 
(SamDC) 
CG5029 
S  
 
 
11366 (#0604) CG10674 CG10674 S 
 
Appendix 
 
46288 (#0622) 
13040 (#7809) 
CG9466 CG9466 
S  
 
 
10468 (#0863) CG5343 CG5343 S 
 
45237 (#0880) CG8401 CG8401 S 
 
31030 (#0969) 
49221 (#0822) 
CG18284 CG18284 
S  
 
 
43250 (#1320) CG3264 CG3264 S 
 
45404 (#1332) CG13423 CG13423 S 
 
50282 (#1638) 
28138 (#6992) 
CG9752 CG9752 
S  
 
 
 
Appendix 
 
44834 (#1978) fizzy (fzy) CG4274 S 
 
30914 (#2071) CG18735 CG18735 S 
 
21120 (#2306) 
47599 (#1495) 
CG30291 CG30291 
S  
 
 
 
47055 (#2310) 
27461 (#7326) 
CG5561 CG5561 
S  
 
 
 
 
8064 (#2371) CG10178 CG10178 S 
 
29765 (#2546) 
48893 (#1653) 
CG9406 CG9406 
S  
 
 
 
34618 (#2782) CG31639 CG31639 S 
 
Appendix 
 
21951( #3053) 
quaking 
related 54B 
(qkr54B) 
CG4816 S 
 
7183 (#3346) 
Catecholamine
s up (Catsup) 
CG10449 S 
 
34308 (#3577) 
COP9 complex 
homolog 
subunit 1 a 
(CSN1a) 
CG4697 S 
 
3886 (#3702) 
Inwardly 
rectifying 
potassium 
channel 3 
(lrk3) 
CG10369 S 
 
46309 (#3893) CG17098 CG17098 S 
 
41463 (#4043) CG10973 CG10973 S 
 
32203 (#4070) CG13502 CG13502 S 
 
Appendix 
 
4542 (#4168) aristaless (al) CG3935 S 
 
15683 (#4652) 
Ribonucleosid
e diphosphate 
reductase 
large subunit 
(RnrL) 
CG5371 S 
 
22994 (#4693) expanded (ex) CG4114 S 
 
37663 (#4732) CG5640 CG5640 S  
 
42798 (#4905) 
DNZDHHC/NE
W1 zinc finger 
protein 11 
(Dnz1) 
CG6627 S 
 
40078 (#5216) 
mind bomb 2 
(mib2) 
CG17492 S 
 
Appendix 
 
14064 (#5341) CG5653 CG5653 S 
 
17005 (#5708) CG10822 CG10822 S 
 
42509 (#5829) CG8370 CG8370 S 
 
46856 (#5897) CG6704 CG6704 S 
 
31394 (#6230) CG11006 CG11006 S 
 
12067 (#6342) CG5366 CG5366 S 
 
3091 (#6394) 
941 (#0244) 
42229 (#7573) 
Fasciclin 3 
(Fas3) 
CG5803 
S 
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16138 (#6459) 
Huntingtin 
interacting 
protein 1 
(Hip1) 
CG10971 S 
 
23742 (#6483) CG9945 CG9945 S 
 
27566 (#6724) 
Leucine-rich 
repeat 47 
(Lrr47) 
CG6098 S 
 
48614 (#6755) CG15168 CG15168 S 
 
8827 (#6969) CG15653 CG15653 S  
 
26027 (#7032) 
Ubiquitin-
specific 
protease 64E 
(Ubp64E) 
CG5486 S 
 
41214 (#7125) CG4953 CG4953 S 
 
Appendix 
 
46064 (#7197) twine (twe) CG4965 S 
 
21970 (#1291) CG4887 CG4887 
S  
 
 
28761 (#7658) CG10576 CG10576 S 
 
39161 (#7773) CG9236 CG9236 S 
 
49674 (#3593) 
34752 (#5664) 
CG17768 CG17768 S  
  
 
 
E-   Enhancement 
S-   Suppression 
L-    Lethal 
SL- Semi-lethal 
NA- Image not available. 
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